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ABSTRACT 
 
Receptor protein tyrosine phosphatase gamma (PTPRG) is a cell surface receptor 
expressed primarily on neurons. It combines cytoplasmic tyrosine phosphatase domains 
and an extracellular region that includes a carbonic anhydrase-like (CA) domain. This 
domain mediates binding to members of a family of neural cell adhesion molecules called 
contactins (CNTNs) that are expressed on neurons during development and adulthood. 
The ectodomains of CNTNs are organized into six N-terminal immunoglobulin domains 
followed by four fibronectin type III repeats (FN) and a glycophosphatidylinositol 
anchor. Previous work demonstrated that PTPRG interacts specifically with CNTN3-6. 
Here, we combine biochemical and structural approaches to further characterize the 
interactions between PTPRG and its cognate CNTN partners. In particular, our work 
indicates that PTPRG associates with CNTN3-6 with similar binding affinities. This 
finding is consistent with our structural analyses of PTPRG•CNTN3 and 
PTPRG•CNTN6 complexes suggesting that CNTN3-6 use a conserved interface to bind 
the CA domain of PTPRG. As a first step to determine the in vivo functions of 
PTPRG•CNTN complexes, we attempted to localize the sites where these receptors 
interact. In particular, we identified the PTPRG•CNTN3 complex in the outer segment 
(OS) of adult mouse retinas. Further investigation of these complexes in the OS revealed 
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that PTPRG and CNTN3 form complexes when expressed on the same cell (cis 
interactions). However, we also performed cell-aggregation assays indicating that 
PTPRG and CNTN3 can associate when expressed on distinct cells (trans interactions). 
To explain how the PTPRG•CNTN3 complex could form in these two distinct 
geometries, we analyzed the conformations taken by the CNTN3 ectodomain. In 
particular, our work indicates that the FN1-FN3 of CNTN3 adopts a bent conformation 
suggesting that the CNTN3 ectodomain bends sharply between FN2 and FN3 domains 
and then extends in parallel to the cell surface. Importantly, this bent conformation is 
found in all six CNTN family members suggesting that all CNTNs might lie parallel to 
the cell membrane. This orientation of CNTN ectodomains would accommodate the 
formation of cis and trans PTPRG•CNTN complexes. Finally, we discuss the 
implications of our results in PTPG/CNTN-mediated signaling. 
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CHAPTER 1 
INTRODUCTION 
Phosphorylation and dephosphorylation in the Nervous system 
The development and maintenance of the nervous system requires a robust set of 
cellular events, such as cell migration, proliferation and maturation, neurite outgrowth 
and synapse formation. At the molecular level these processes are driven by extra- and 
intracellular cell signaling. The accuracy of these signaling events is an essential element 
for the precise regulation of nervous system development and its functionality.  
Reversible protein phosphorylation is an essential signaling mechanism, utilized 
by nearly all living cells in metazoans, including neural cells. Protein phosphorylation is 
catalyzed by a class of enzymes called protein kinases. A change in phosphorylation state 
may modulate the activity of a protein and/or create docking sites for specific binding 
partners. An example of a kinase-mediated activation in the nervous system is the 
neurotrophic receptor tyrosine kinase A (TrkA), a receptor for nerve growth factor (NGF) 
discovered in the 1950s (Levi-Montalcini, 1952). Upon ligand binding, TrkA dimerizes 
and activates itself by tyrosine cross-autophosphorylation. Phosphorylated Y490 and 
Y785 residues serve as docking sites for several binding partners, such as the Grb2 
adaptor protein (ERK signaling pathway), phospholipase C-γ (PLCγ) and 
phosphoinositide-3 kinase (PI3K); these interactions in turn launch corresponding 
signaling cascades that result in various cellular events (Arévalo and Wu, 2006). In 
contrast, the proteins responsible for dephosphorylation are called phosphatases. Kinases 
and phosphatases work in tandem to maintain the necessary balance between 
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phosphorylated and dephosphorylated forms of the proteins. Together, they guide the 
cellular processes necessary for the development and maintenance of all tissues and in 
particular the nervous system. Protein phosphatases are organized into evolutionarily 
distant families that include serine/threonine phosphatases, tyrosine phosphatases, and 
dual-specificity phosphatases (Tonks, 2006). Both kinases and phosphatases may exist 
as either receptor or non-receptor forms. Receptor forms are particularly interesting 
because they signal across the membrane and extracellular cues to intracellular enzymatic 
activity. The work presented in this dissertation is focused on Receptor Protein Tyrosine 
phosphatases (RPTPs) – the subset of glycoproteins that combine both an extracellular 
receptor ectodomain and an intracellular phosphatase region.  
General properties of RPTPs  
RPTPs belong to the family of classical Protein Tyrosine Phosphatases (PTPs), 
which is defined by the presence of a canonical membrane-proximal phosphatase domain 
(D1) with the signature (I/V)HCSxGxGR(S/T)G motif (Andersen et al., 2004; Tonks, 
2006). All RPTPs are grouped into 8 different subtypes (Fig. 1) based on their structural 
organization (Nam, 2005). In addition to catalytic D1 domain, more than one half of 
known RPTPs are characterized by an additional membrane-distal phosphatase domain 
– D2, which is usually inactive except in the case of PTPRA (Tonks, 2006). Apart from 
the cytoplasmic phosphatase domains, RPTPs also include an extracellular receptor 
portion variable in different subtypes of RPTPs. The ectodomains of RPTPs might 
provide an additional mode of the phosphatase activity regulation through ligand binding.  
Importantly, the extracellular region of most RPTPs resembles the ectodomains of cell  
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 adhesion molecules, which presumably indicates that RPTPs participate in cell-cell and 
cell-matrix contact events (Burridge et al., 2006; Sallee et al., 2006). 
Whereas the mechanism of regulation of kinase receptors through ligand-induced 
oligomerization is well described (Schlessinger, 2014), the regulation of RPTPs by the 
same mechanism remains unclear. Moreover, it appears that distinct receptor 
phosphatases might utilize different strategies for the regulation of their phosphatase 
activity through the binding of extracellular ligands, oligomerization, reversible 
oxidation and phosphorylation (Tonks, 2006). The mode of RPTP regulation by 
oligomerization was originally proposed in the structural study of CD45 phosphatase 
(Desai et al., 1993). In this study the intracellular region of CD45 that included tandem 
phosphatase domains D1 and D2 was attached to the extracellular and transmembrane 
domains of the EGF receptor (EGFR). EGFR/CD45 chimera restored T-cell receptor 
(TCR) signaling in CD45-null cells, indicating the autonomy of phosphatase signaling 
relative to its native extracellular domain. Moreover, EGF stimulation of the chimera 
leads to the repression of TCR signaling, indicating a mode of regulation through ligand-
induced oligomerization similar to what has been described for EGFR. However, recent 
studies have shown that a long and rigid ectodomain of CD45 is sterically excluded from 
sites of TCR-ligand engagement that leads to segregation of CD45 and the tyrosine 
kinase Lck. This shifts an equilibrium towards TCR phosphorylation by Lck and further 
activation of TCR (Chang et al., 2016). Other findings suggest that Lck should be 
dephosphorylated by CD45 to be able to activate TCR signaling (Hermiston et al., 2003). 
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Therefore, the repression of TCR signaling upon EGF stimulation of the EGFR/CD45 
chimera might be caused by its failure to activate Lck. 
Although the dimer formation for CD45 has been shown to inhibit the 
phosphatase activity, the structural basis for the RPTPs regulation though the 
oligomerization was unclear. One of the first structural insights into the oligomerization-
induced inactivation of RPTPs comes from PTPRA (Bilwes et al., 1996). The crystal 
structures of the D1 domain of PTPRA domain revealed a dimer that was observed in 
three different space groups. The active site of each D1 monomer in the dimer was 
occluded by the N-terminal helix-turn-helix region of another D1 monomer, named 
“wedge” based on its shape (Fig. 2). This raised the possibility that the phosphatase 
activity of RPTPs is inhibited by oligomer formation and subsequent occlusion of the 
active site by the wedge from the opposing monomer.  
However, the proposed wedge model had some limitations. The crystal structure 
of PTPRA was obtained solely for the D1 domain and did not include the D2 domain 
(Sonnenburg et al., 2003). Moreover, the model of wedge inhibition was not supported 
by the structural analyses of the D1-D2 tandem domains for LAR and CD45 
phosphatases (H. J. Nam et al. 1999; H. J. Nam 2005). The superimposition of the LAR 
and CD45 D1-D2 domain crystal structures on the corresponding PTPRA D1 crystal 
structure revealed steric clashes between the opposite D2 domains so that the model of 
wedge inhibition cannot apply to either LAR or CD45. In the large-scale structural 
analyses of tyrosine phosphatase domains (Barr et al., 2009), none of the obtained crystal 
structures of RPTPs dimerized via the wedge region as is the case for PTPRA D1. 
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Subsequent analytical ultracentrifugation experiments revealed that the tandem 
phosphatase domains for most of RPTPs are monomeric in solution. A monomeric state 
in solution has been confirmed for IA2, IA2β, GLEPP1, DEP1 and STEP single-
phosphatase domain RPTPs, as well as for CD45, PTPRE, and PTPRM tandem-
phosphatase domain RPTPs.  These findings suggest an alternative mechanism to the 
previously established model of the inhibitory wedge, which may include the binding of 
an extracellular ligand followed by ectodomain oligomerization, proteolysis, and 
oligomerization under an oxidative stress conditions (Barr et al., 2009).  
Even though the tyrosine phosphatase domains appear monomeric in solution, the 
intact RPTPs might still be regulated by ligand-induced oligomerization. For example, 
an association of type IIa RPTPs (LAR, PTPRS, PTPRD) with proteoglycans modulates 
their activity. The binding of heparan sulfate proteoglycans (HSPGs) induces 
oligomerization and clustering of PTPRS phosphatase molecules and presumably 
decreases their activity, creating zones of increased phosphorylation and promoting axon 
outgrowth. In contrast, the binding of chondroitin sulfate proteoglycans (CSPGs) to 
PTPRS stabilizes phosphatase molecules in a monomeric state maintaining a constitutive 
phosphatase activity and inhibiting axonal extensions (Coles et al., 2011).   
An oxidative stress regulation model, which has been proposed for PTPRA, 
suggests an equilibrium between monomeric and dimeric forms of the membrane-bound 
phosphatase. The treatment of PTPRA by H2O2 oxidizes the D2 active site Cys723 
residue that triggers a conformational change in the D2 domain.  This leads to the 
stabilization of the catalytically inactive dimeric conformation by the formation of a 
 6 
 
disulfide bond between the Cys723 residues of two D2 domains (Blanchetot et al., 2002; 
Tonks, 2006). 
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Figure 1. Structural organization of Receptor Protein Tyrosine Phosphatases. Eight 
families of RPTPs are expressed in nervous system and participate in various cellular 
events that involve neuronal survival, synapse formation, axon targeting and neurite 
outgrowth (Mohebiany et al., 2013). 
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Figure 2. PTPRA D1 domain forms an autoinhibitory dimer. Crystal structure (PDB 
ID: 1YFO) of the PTPRA D1 domain (Bilwes et al., 1996) is shown in ribbon diagram 
and colored in cyan. N-terminal loop-helix-loop wedge (blue) occludes the active site of 
the opposing PTPRA D1’monomer. PTPRA D1 active site is represented by the key 
catalytic residues shown in spacefill - Cys433 (magenta) and Asp401 (green). 
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PTPRZ and PTPRG 
PTPRG and PTPRZ are two phosphatases that form the type V subfamily of 
RPTPs. PTPRG and PTPRZ share a common structural organization and consist of a 
carbonic anhydrase (CA) domain, a fibronectin type III (FN) repeat, a spacer region, a 
transmembrane domain and tandem intracellular tyrosine phosphatase domains (Fig. 1, 
5) (Krueger and Saito, 1992; Barnea et al., 1993; Bouyain and Watkins, 2010). Both 
phosphatases are highly expressed in the developing and adult nervous system. In the 
nervous system, PTPRZ is mostly localized to glial cells while PTPRG is predominantly 
expressed on neurons (Canoll et al., 1996; Lamprianou et al., 2006). However, PTPRZ 
can also be expressed in subsets of neurons (Hayashi et al., 2005), whereas PTPRG may 
also be upregulated in certain types of glial cells, including small astrocytes during 
neuroinflammatory conditions such as lipopolysaccharide (LPS) treatment or in an 
Alzheimer’s disease murine model (Lorenzetto et al., 2013). 
PTPRG is the only RPTP whose tandem phosphatase domains have been shown 
to dimerize in solution (Barr et al., 2009). The crystal structure of PTPRG phosphatase 
domains revealed that D1-D2 domains are organized in a head-to-toe orientation. In this 
conformation, the catalytic site of each D1 active phosphatase domain is occluded by the 
symmetry-related inactive D2 domain (Fig. 3). Structure-based mutations at the PTPRG 
dimer interface impaired dimer formation as judged by an analytical ultracentrifugation 
experiments; this indicated that the dimers identified in the crystal structure are identical 
to those in solution.  The dissociation constant (Kd) for the dimer of PTPRG is 3.5 µM 
suggesting that it exists in a monomer-dimer equilibrium at the cell membrane. It has 
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been proposed that ligand binding to PTPRG shifts the equilibrium towards the inactive 
dimeric conformation (Fig. 4) (Barr et al., 2009). Interestingly, in the PTPRG head-to-
toe occlusion model each active site of D1 domain is occluded by the loop from the 
opposing D2 domain that contains a tyrosine residue (Y1307), which in turn has shown 
to be a site for PTPRG auto-dephosphorylation (Zhang et al., 2012). Therefore, dimer 
formation of PTPRG and the regulation of its phosphatase activity may also be coupled 
to increased tyrosine phosphorylation of PTPRG substrates while PTPRG 
dephosphorylates itself. 
It is likely that PTPRZ (RPTPζ), the closest homolog of PTPRG, might be 
regulated in a manner similar to PTPRG. Although no structural data suggesting the same 
behavior for PTPRZ have been obtained, sequence alignments of PTPRG and PTPRZ 
have shown that key residues required for the formation of the D1-D2 phosphatase dimer 
are conserved (Barr et al., 2009). It has been shown that PTPRZ is inactivated by the 
heparin-binding growth factor pleiotrophin (PTN) and by the VacA cytotoxin secreted 
by Helicobacter pylori (Fukada et al., 2006; Barr et al., 2009). PTN binding to the 
extracellular portion of PTPRZ results in increased phosphorylation of PTPRZ 
downstream substrates Git1 and Magi1, indicating that its phosphatase activity is 
inhibited. The visualization of PTPRZ distribution upon PTN binding revealed the 
clustering of phosphatase molecules suggesting that ligand binding induces dimerization 
as well as inhibition of phosphatase activity. Similar results were obtained in an artificial 
dimerization system in which the D1-D2 domains of PTPRZ were fused to the 
intracellular domains of FKBP that forms a dimer upon the stimulation by the AP20187 
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(ARGENTTM Regulated Homodimerization Kit). Finally, the treatment by polyclonal 
antibody also inactivated PTPRZ suggesting the inhibitory effect of ligand-induced 
oligomerization (Fukada et al., 2006). Thus, the potential of PTPRG and PTPRZ to form 
D1-D2 phosphatase dimers provides an alternative mode of a ligand-dependent RPTP 
regulation that should be further investigated. 
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Figure 3. PTPRG D1D2 domains form a dimer on the head-to-toe orientation. 
Crystal structure (PDB ID: 2NLK) of PTPRG D1D2 domains (Barr et al., 2009) is shown 
in ribbon diagram. PTPRG D1 domain is colored in cyan, D2 is colored in red. D1D2 
domains form a dimer with a symmetry related mate D1’D2’ that results in the occlusion 
of D1 active site. The PTPRG D1 active site is represented by the key catalytic residues 
shown in spacefill – Cys1060 (magenta) and Asp1028 (green). The D2 occluding loop is 
represented by Tyr1307 residue (spacefill, orange), which has shown to be auto-
dephosphorylated in PTPRG.  
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Figure 4. A model for PTPRG ligand-induced dimerization. Hypothetical model of 
the PTPRG/PTPRZ catalytic inactivation through the ligand-induced oligomerization 
(Barr et al., 2009). Graphical representations of PTPRG/PTPRZ domains are shown in 
ribbon diagram. CA domain is colored in green, FN domain – in forest, TM domain – in 
orange, D1 domain in – cyan, D2 domain in red.  
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PTPRG and PTPRZ binding partners 
Several ligands have been characterized for PTPRZ. In addition to previously 
mentioned heparin-binding growth factors PTN and VacA cytotoxin, PTPRZ also binds 
extracellular matrix (ECM) protein tenascin and several members of the immunoglobulin 
superfamily of CAMs (Ig-CAMs). The first ligand discovered for PTPRZ was Contactin 
(CNTN1), which was also the first binding partner characterized for any RPTP (Peles et 
al., 1995). Further studies showed that the PTPRZ•CNTN1 complex is implicated in the 
maturation of oligodendrocyte precursor cells (OPCs) and the differentiation of 
oligodendrocytes (Lamprianou et al., 2011). These findings are consistent with data 
indicating that mice lacking PTPRZ exhibit impaired recovery from demyelinating 
lesions (Harroch et al., 2002). In contrast to PTPRZ, the binding partners of PTPRG have 
not been extensively characterized. Based on the interaction of PTPRZ and CNTN1 it 
was predicted that the CA domain of PTPRG might interact with some members of 
CNTN family. Indeed, subsequent in vitro analyses indicated that the CA domain of 
PTPRG bound to specifically to CNTN3, 4, 5 and 6, but not CNTN1 (Bouyain and 
Watkins, 2010).  
The six CNTNs belong to the Ig-CAMs superfamily and are composed of 6 N-
terminal immunoglobulin-like (Ig) domains, 4 fibronectin type III domains (FN), and a 
glycophosphatidylinositol (GPI)-anchor, which tethers them to a membrane (Fig. 5). 
CNTNs are expressed on the surface of neurons at a multitude of sites in the nervous 
system during development and adulthood. They are involved in various 
neurodevelopmental processes such as neural cell migration and proliferation, myelin 
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sheath formation, synaptogenesis and axon guidance (Shimoda and Watanabe, 2009). 
CNTN3-6, the binding partners of PTPRG, display partially overlapping spatiotemporal 
expression patterns in the nervous system. CNTN3 is the least studied member of the 
CNTN family. It is expressed in adult brain in a certain subset of neurons, including 
Purkinje cells of the cerebellum, granular cells of hippocampus and neurons of the 
cerebral cortex (Yoshihara et al., 1994; Shimoda and Watanabe, 2009). CNTN4 is best 
known for its expression in the mouse olfactory system and is found in certain 
subpopulations of olfactory sensory neurons (OSNs). Despite a normal gross brain 
anatomy, CNTN4 deficient mice exhibit abnormalities in axonal projections of OSNs to 
multiple glomeruli suggesting a role for CNTN4 in the formation of odor maps (Kaneko-
Goto et al., 2008). Recently, CNTN4 was discovered in retinal ganglion cells (RGC), 
where it is crucial for RGC axon targeting to the nucleus of the optic tract, the region 
responsible for horizontal image stabilization during the processing of a visual signal 
(Osterhout et al., 2015). CNTN5 expression was characterized in developing 
glutamatergic synapses of the adult rat auditory pathway. The characterization of CNTN5 
deficient mice mutants did not reveal significant anatomical brain abnormalities. 
However, mutant mice exhibited impaired processing of acoustic stimuli in the brain 
(Toyoshima et al., 2009). The sites of CNTN6 mRNA expression include the olfactory 
bulb, certain layers of the cerebral cortex, cerebellum and some other regions of the brain 
(Lee et al., 2000). Similarly to CNTN4 and CNTN5 mutants, CNTN6 deficient mice 
showed no gross abnormalities in brain development. However, CNTN6-/- animals 
demonstrated some defects in motor coordination (Takeda et al., 2003). This may be 
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associated with the role of CNTN6 in forming of glutamatergic synapses between 
specific subsets of neurons (Purkinje cells and parallel fibers of granule cells) during 
development of the cerebellum (Sakurai et al., 2009).  A broader look at the role of 
CNTN3-6 in mammalian brain function and development suggests they play a specific 
role in transmission and processing of sensory signals, motor activity, and higher 
cognitive function.  
Although it is known now that CNTN3-6 bind PTPRG in vitro, there is no 
evidence that the same binding event occurs on the cell surface. Moreover, the 
physiological roles these complexes might play remain unknown. Interestingly, the 
expression pattern of PTPRG in the nervous system partially overlaps with the sites of 
CNTN3-6 expression. It is expressed in pyramidal neurons of the cerebral cortex and 
hippocampus as well as in RGCs, olfactory bulb glomerulus cells, and ear sensory cells 
(Lamprianou et al., 2006). Similarly to CNTN4-6 mutants, tissue analysis did not uncover 
any visible abnormality for nervous system development in PTPRG-/- mice. Comparative 
behavioral analyses have shown only mild changes in PTPRG mutants (Lamprianou et 
al., 2006). At the same time, both the PTPRG knockdown and the phosphatase-inactive 
mutant forms of PTPRG (C1060S) have been shown to produce the antidepressive-like 
phenotype in mice. In addition to antidepressive behavior, the complete loss of PTPRG 
resulted in increased locomotor activity; this was not detected in mice expressing a 
catalytically inactive form of PTPRG indicating that PTPRG can be involved in signaling 
events independent from its primary catalytic activity (Zhang et al., 2012). 
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Figure 5. Structural organization of type V RPTPs and their binding partners 
CNTNs. PTPRG/Z phosphatases include a carbonic anhydrase domain (CA), 
fibronectin-like type III domain (FN), a spacer region, a transmembrane domain and two 
phosphatase domains (D1 and D2). PTPRG/Z binds the members of CNTN family that 
contain 6 immunoglobulin-like domains (Ig) and 4 FN domains. CNTNs do not have an 
intracellular domain and tethered to a membrane with a glycophosphatidylinositol (GPI) 
anchor. 
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Conclusions 
RPTPs are unique proteins that combine an intracellular phosphatase activity with 
an extracellular receptor moiety. PTPRG and PTPRZ are two members of the type V 
family of RPTPs that bind to CNTN family members in vitro. PTPRZ binds CNTN1, 
whereas PTPRG binds CNTN3-6. The role of the PTPRZ•CNTN1 complex in OPC 
proliferation and maturation has been extensively studied, but the function for PTPRG 
binding to CNTN3-6 is poorly understood.  Moreover, there is still no data confirming 
that PTPRG•CNTN binding occurs on the cell surface. It would be very useful to obtain 
more structural information about the geometry of these complexes to have a better 
understanding of the possible outcomes from any PTPRG•CNTN binding event. In 
particular, CNTNs may act as regulators of PTPRG phosphatase activity or co-receptors 
together with the PTPRG ectodomain.  Another question is the reason for the apparent 
redundancy of having four highly homologous molecules bound to the same PTPRG 
molecule. This work is intended to obtain more structural and biochemical insights into 
the interactions between CNTNs and PTPRG, as well as to shed light on the possible 
functional significance of these complexes. 
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CHAPTER 2 
MATERIAL AND METHODS 
Protein expression and purification 
Mouse CNTN5(Ig1-Ig4) was transiently expressed using the pSGHP1 vector as 
a fusion protein with human growth hormone (hGH), an octahistidine tag, and a human 
rhinovirus 3C protease site. N-acetylglucosaminyltransferase I-negative HEK293S cells 
were used for protein expression. The resulting protein was cleaved with human 
rhinovirus 3C protease, deglycosylated using endoglycosidase H, and immobilized by 
metal affinity and ion exchange chromatography. The purification was completed by 
size-exclusion chromatography using a Superdex 200 26/60 column (GE Healthcare) 
equilibrated in 20 mM Tris-HCl, pH 8.0 and 200 mM NaCl (Bouyain and Watkins, 2010). 
Mouse CNTN3(Ig2-Ig3) and mouse CNTN6(Ig2-Ig3) were expressed in Escherichia coli 
strain T7 Shuffle Express cells (New England Biolabs) using the pT7HMP vector. 
Proteins were expressed as hexahistidine fusion proteins with a human rhinovirus 3C 
protease site. After proteolytic cleavage, proteins were purified by metal affinity, ion 
exchange and size exclusion chromatographies (Bouyain and Watkins, 2010).  
Mouse and human PTPRG(CA) were expressed as fusion proteins with a 
thioredoxin tag, a hexahistidine tag, followed by a human rhinovirus 3C protease site in 
Escherichia coli strain Origami 2 (DE3) using a modified version of the pET32 plasmid 
(Novagen). The proteins were released  from the thioredoxin tag following cleavage by 
human rhinovirus 3C protease and purified metal affinity, ion exchange, and size 
exclusion chromatographies (Bouyain and Watkins, 2010).  
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Complexes of mouse CNTN3(Ig2-Ig3) and human PTPRG(CA) and of mouse 
CNTN3(Ig2-Ig3) with mouse PTPRG(CA) were prepared by mixing the corresponding 
purified proteins in equimolar ratios and further purification by gel filtration using a 
Superdex 200 26/60 column (GE Healthcare) in equilibrated in 20 mM Tris-HCl, pH 8.0 
and 200 mM NaCl. 
Full-length mouse CNTN3, 4, 5, and 6 fused to a human IgG Fc were expressed 
transiently in HEK293 cells. Conditioned media was dialyzed against a solution of 200 
mM NaCl and 20 mM Tris-HCl pH 8.0, which also served as a binding buffer. Proteins 
were purified by affinity chromatography using protein A UltraLink resin (Pierce). 
Bound proteins were eluted with 0.1 M Glycine-HCl pH 2.0 and neutralized immediately 
with 1 M Tris base (Bouyain and Watkins, 2010). 
A mutant form of mouse PTPRG(CA) was engineered with a C-terminal cysteine 
for the production of biotinylated PTPRG(CA), because free sulfhydryl groups react 
specifically with maleimide groups at pH 7.0. The protein was expressed in Escherichia 
coli strain Origami 2 (DE3) cells. The expression and purification process was the same 
as described for the wild type PTPRG(CA), except the buffers were prepared at pH 7.0 
to prevent the formation of disulfide dimers. After an ion-exchange purification step, the 
protein was mixed with EZ-link Maleimide-PEG2k-Biotin reagent according to 
manufacturer’s instructions and then further purified by gel filtration. 
Mouse PTPRG(CA) mutants cDNAs were generated by PCR using the 
megaprimer approach (Sarkar and Sommer, 1990). The mutants included the following 
mutations: H295A+V296A and H226A+K229A. A cDNA for the β-hairpin deletion 
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mutant of mouse PTPRG(CA) with the residues E291QQDHVKSV299 was replaced by 
Ala-Ser-Ala (ASA) sequence was generated by overlapping extension PCR. The cDNAs 
were subcloned into the modified pET32 plasmid mentioned above (Novagen). The 
proteins were expressed and purified as described for the wild-type PTPRG(CA). 
Domains FN1-FN3 for chick CNTN1, human CNTN5 and mouse CNTN2, 3, 4 
and 6 were expressed as fusion proteins with a hexahistidine tag and rhinovirus 3C 
protease site using pT7HMP vector in E. coli strain BL21 (DE3). The methionine 
auxotroph E. coli strain B834(DE3) was used for the production of selenomethionine-
labeled CNTN2(FN1-FN3). Proteins were proteolytically cleaved and purified using 
metal-affinity, ion-exchange, and size exclusion chromatographies. 
Crystallization and structure determination 
All crystals were grown at 20⁰C by hanging drop diffusion. Crystallization and 
cryoprotection conditions for each protein or protein complex are listed in Table 1. X-
ray diffraction data were collected at 1.00 Å at Southeast Regional Collaborative Access 
Team (SER-CAT) beamlines 22-ID and 22-BM at the Advanced Photon source of 
Argonne National Laboratory. Diffraction data were processed with HKL2000 software 
(Otwinowski and Minor, 1997).  All structures except mouse CNTN2(FN1-FN3) were 
solved by molecular replacement using PHASER (McCoy et al., 2007) software from the 
PHENIX suite (Adams et al., 2010). The initial model for the FN1-FN3 fragment of 
mouse CNTN2 was obtained by single-wavelength anomalous diffraction using data 
collected from a crystal grown with selenomethionine-labeled protein. The initial 
solution was obtained using the PHENIX AutoSol and AutoBuild routines. The BAYES 
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correlation coefficient and figure of merit for the solution were 45.6 ± 20.4 and 0.25, 
respectively. Models were manually built in COOT software (Emsley and Cowtan, 2004) 
and refined by PHENIX. Models were validated for Ramachandran statistics and 
geometry using the RSCB Protein Data Bank validation server. Superimposition of 
obtained structures was made by the DaliLite server (Hasegawa and Holm, 2009). 
Interface area and polar interactions were calculated by the PISA server (Krissinel and 
Henrick, 2007). CCP4 software was used to identify contact residues (Winn et al., 2011). 
Shape complementarity coefficients were calculated by SC program (Lawrence and 
Colman, 1993). Graphical representations of structures were generated by PyMol 
(www.pymol.org). 
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TABLE 1 
 
CRYSTALLIZATION AND CRYOPROTECTION CONDITIONS 
 
Protein / Protein complexes  Conc. (µM) Crystallization condition Cryoprotection solution 
Human PTPRG(CA) and mouse 
CNTN3(Ig2-Ig3) 
50 
1% (v/v) Tacsimate pH 7.0,  1% Tacsimate pH 7.0,  
20% (w/v) PEG 3,350,  20% PEG (w/v) 3,350,  
50mM Imidazole-HCl pH 6.5 50mM Imidazole-HCl pH 6.5  
   15% (w/v) PEG 400 
Mouse PTPRG(CA) and mouse 
CNTN6(Ig2-Ig3) 
100 
55% (v/v) Tacsimate pH 7.0,  55% Tacsimate pH 7.0,  
150 mM NDSB 201  150 mM NDSB 201,  
  20% (v/v) Glycerol 
Mouse CNTN5(Ig1-Ig4) 
40 
 
7% (v/v) Tacsimate pH 7.0,  50mM Imidazole pH 7.0,  
15% (w/v) PEG 3,350,  5% (v/v) Tacsimate pH 7.0,  
50 mM Imidazole pH 7.0 15% (w/v) PEG 3,350,  
  20% (v/v) Glycerol 
Chicken CNTN1(FN1-FN3) 260 
1% (v/v) Tacsimate pH 7.0,  50 mM Imidazole pH 6.5,  
20% (w/v) PEG 3,350,  9% (w/v) PEG 3,350,  
50mM Imidazole pH 6.5 21% Glycerol  
Mouse CNTN2(FN1-FN3) 230 
50 mM NH4Cl,  50 mM Tris-HCl pH 8.5,  
50 mM Tris-HCl pH 8.5,  10% (w/v) PEG 4,000,  
10% (w/v) PEG 4,000,  25% (v/v) glycerol 
2% (v/v) glycerol   
Mouse CNTN3(FN1-FN3) 200 
10% (w/v) PEG 1,500,  25% (w/v) PEG 1,500,  
50 mM Na-cacodylate pH 6.5 50 mM Na-cacodylate pH 6.5,  
  10% (v/v) glycerol 
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“TABLE 1 -- Continued.” 
 
CRYSTALLIZATION AND CRYOPROTECTION CONDITIONS  
 
Protein / Protein complexes  Conc. (µM) Crystallization condition Cryoprotection solution 
Mouse CNTN4(FN1-FN3) 180 
100 mM (NH4)2SO4,  25 mM (NH4)2SO4,  
50 mM Tris-HCl pH 8.5,  50 mM Tris-HCl pH 8.5,  
10% (w/v) PEG 4,000 10% (w/v) PEG 4,000,  
  25% (v/v) glycerol 
Human CNTN5(FN1-FN3) 270 
1.0 M NH4H2PO4,  1.0 M NH4H2PO4,  
10% (v/v) Tacsimate pH 5.0  10% (v/v) Tacsimate pH 5.5,  
  38% (w/v) sorbitol 
Mouse CNTN6(FN1-FN3) 25 
300 mM Na-Malonate pH 7.0,  15% PEG 400,  
20% (w/v) PEG 3,350,  20% (w/v) PEG 3,350,  
50 mM Na-Cacodylate pH 6.5 250 mM Na-Malonate pH 7.0,  
  50 mM Na-Cacodylate pH 6.5 
Mouse CNTN3(Ig5-FN2) 100 
7.5% (w/v) PEG 8,000, 7.5% (w/v) PEG 8,000, 
50 mM Imidazole pH 7.5 50 mM Imidazole pH 7.5 
 15% (v/v) glycerol 
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AlphaScreen binding assays 
The AlphaScreen binding assay (PerkinElmer Life Sciences) is based upon the 
interaction between a ligand immobilized on donor beads and a second protein bound to 
acceptor beads (Fig. 6). Upon illumination at 680 nm, phthalocyanine from the donor 
beads converts ambient oxygen to its singlet form, which travels approximately 200 nm 
in solution. If there is an acceptor bead within that distance, the singlet oxygen will 
activate thioxene derivatives within the acceptor bead, and a luminescent signal at 520-
620 nm will be emitted. Thus, the signal is produced when donor beads are proximal to 
acceptor beads, which results from the interaction between proteins immobilized on the 
bead surfaces.  
The assay was designed in 96-well plate format (PerkinElmer Life Sciences semi-
opaque microplates) and was based on inhibiting the signal obtained from the interaction 
of biotinylated PTPRG bound to streptavidin-coated donor beads, and IgG FC fused 
CNTN3, 4, 5 or 6 bound to protein A-coated acceptor beads. Both types of beads were 
obtained from an AlphaScreen general IgG (Protein A) detection kit from PerkinElmer 
Life Sciences. Final reaction volumes were kept at 25 µl for all experiments. Initially, 5 
µl of biotinylated mouse PTPRG(CA) (5 nM final concentration) were mixed with 5 µl 
of human IgG FC-fused CNTN3, 4, 5 or 6 and incubated with 5 µl aliquots of untagged 
wild-type PTPRG(CA) of varying concentrations. After a 1-hour incubation at room 
temperature protein A-coated acceptor beads (5 μl, 20 µg/ml final concentration) were 
added to each well. After another 1-hour incubation, streptavidin-coated donor beads (5 
μl, 20 µg/ml final concentration) were added to each well. The reactions were allowed to 
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stand at room temperature for 30 minutes prior to transferring to 96-well ½ area opaque 
microplates for detection using an EnSpire multimode plate reader (PerkinElmer Life 
Sciences). Values for normalized binding were calculated by dividing the signal 
measured for a reaction without inhibitor. For the control experiment, bovine carbonic 
anhydrase II was used as an inhibitor in the equivalent assay. Results were fitted to a one-
site competition equation, in which the IC50 is the concentration of inhibitor that gives 
50% inhibition of maximal binding using GraphPad Prism (GraphPad). The values of 
IC50 are reported as averages ± standard deviations of at least three experiments.  
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Figure 6. AlphaScreen technology (Perkin Elmer) based competition assay design. 
Biotinylated PTPRG(CA) protein bound to streptavidin donor bead interacts with the 
CNTN3 to 6 expressed as fusion proteins with human IgG FC tag, which binds to protein 
A-coated acceptor bead. Under these conditions, excitation of donor beads at 680 nm 
triggers the release and migration of singlet oxygen to acceptor beads followed by a 
signal emission at 520-620 nm. Based on the inhibition of the produced signal by either 
untagged PTPRG(CA) or control bovine CAII competition curves were obtained and IC50 
values were determined. 
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Small angle X-ray scattering (SAXS) 
SAXS data were collected at the ALS beamline 12.3.1 LBNL Berkeley, 
California (Hura et al., 2011). The wavelength λ and the sample-to-detector distances 
were set to 1.03 Å and 1.5 m, respectively, resulting in scattering vectors q ranging from 
0.01 Å-1 to 0.32 Å-1. The scattering vector is defined as q = 4π sinθ/λ, where 2θ is the 
scattering angle. All experiments were performed at 20 °C and data was processed as 
described (Hura et al., 2011). Data acquired for 0.5, 1, and 2 M concentrations were 
merged for calculations using the entire scattering profile. The protein was prepared by 
size exclusion chromatography on a Superdex 200 10/30 HR column (GE Healthcare) 
equilibrated in 20 mM Tris-HCl pH8.0, 200 mM NaCl prior to data collection. The 
experimental SAXS data for different protein concentrations were analyzed for 
aggregation using Guinier plots (Guinier and Fournet, 1956). The radius of gyration RG 
is 30.9 Å and was derived by the Guinier approximation I(q) = I(0) exp(-q2RG
2/3) with 
the limits qRG < 1.6. The theoretical SAXS profile and the corresponding fit to the 
experimental data were calculated using the program FoXS (Schneidman-Duhovny et al., 
2013). A molecular envelope for CNTN3(FN1-FN3) was calculated from the 
experimental scattering data using the program DAMMIF and averaged using 
DAMAVER (Volkov and Svergun, 2003; Franke and Svergun, 2009). The molecular 
envelope and the crystal structure of CNTN3(FN1-FN3) were superimposed using 
Chimera (Pettersen et al., 2004). 
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Cell binding assays  
HEK293 cells were maintained in DMEM high glucose supplemented with 10% 
(v/v) of fetal bovine serum. GPI-anchored mouse CNTNs were transiently expressed in 
HEK293 cells (Fig. 7) as fusion proteins with hGH as described previously (Bouyain and 
Watkins, 2010). A fragment of human PTPRG including its CA and FN domains fused 
to human IgG FC was incubated in the presence of fluorescein isothiocyanate-labeled 
anti-human Fc antibodies (Jackson) for 30 minutes. The labeled PTPRG was added to 
the transfected cells for 15 minutes in DMEM/F12 containing 1% N2 supplement at room 
temperature and then fixed in 4% (w/v) paraformaldehyde (PFA) in PBS for 10 minutes. 
The presence of transfected proteins was detected by immunostaining against hGH using 
a rabbit polyclonal antibody (Fitzgerald) (Hamaoka et al., 2004; Bouyain and Watkins, 
2010). 
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Figure 7. Cell binding assays design. CNTNs fused to hGH were transiently expressed 
on the surface of HEK293 cells. The expression of CNTNs was detected by the 
immunostaining against hGH with the rabbit polyclonal antibody (green).  A recombinant 
protein consisting of CA and FN domains of PTPRG was expressed as a fusion with a 
human IgG Fc fragment and incubated with fluorescein isothiocyanate-labeled anti-
human Fc antibodies (magenta). The labeled PTPRG(CA-FN)-Fc protein was applied to 
the surface of the transfected HEK293 cells.  The binding was detected using the 
immunohistochemistry protocol.  
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Immunostaining of mouse adult retinas and proximity ligation assays 
Retinas were obtained from adult C57BL6 mice (> 8 weeks old) from the Jackson 
Laboratory. All studies followed the guidelines prescribed by the UMKC IACUC and 
the U.S. National Institutes of Health/National Eye Institute. Adult mice were deeply 
anesthetized with CO2, eyes were enucleated, and the cornea and lens were removed. All 
eyecups were rapidly fixed for 15 min in 4% (w/v) PFA and processed as previously 
described for immunohistochemistry (Stella et al., 2012). Solitary rod photoreceptors 
were dissociated from isolated retina as previously described (Zayas-Santiago and Kang 
Derwent, 2009) and fixed for 10 minutes in 4% (w/v) PFA, washed in PBS and processed 
for indirect immunofluorescence or Duolink™ analysis. 
All tissue was labeled using the indirect immunofluorescence technique using 
goat anti-CNTN3 (1:200, R&D systems) and mouse anti-PTPRG (1:80, Novus 
Biologicals) as described previously (Stella et al., 2012). The primary antibody/antigen 
complexes were detected using secondary antibodies conjugated to CF488 and CF568 
(Biotium). In situ proximity ligation assays (PLAs) were performed to detect in vivo 
interactions between PTPRG and CNTN3 using the primary antibodies and dilutions 
mentioned above. Retinas were labeled using DuoLink™ in situ reagents from Olink 
Bioscience according to the manufacturer’s instructions. A fluorescent signal is obtained 
when the labeled proteins are within 40 Å of one another. In control experiments, primary 
antibodies were omitted and only secondary antibodies and Duolink reagents were 
included in the subsequent steps to rule out spurious non-specific labeling. All images 
were acquired sequentially using a Nikon C2 confocal microscope with appropriate lasers 
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for excitation (e.g, 488 and 561 nm) and filters (e.g., 505-530BP and 565-600BP 
respectively) for emission collection as either 12-bit or 8-bit signals. Images were 
processed for publication using Fiji (Schindelin J, Arganda-Carreras I, Frise E, Kaynig 
V, Longair M, Pietzsch T, 2003). 
Cell aggregation assays 
 cDNAs encoding full-length mouse CNTN1, CNTN3 and PTPRG without their 
signal sequences were cloned into the mammalian expression vectors pSmEmerald 
(CNTN1, 3) and pSmCherry (PTPRG) designed in the laboratory. These vectors derive 
from the pLEXm plasmid (Aricescu et al., 2006) and direct the expression of the chicken 
PTPRS signal sequence followed by a monomeric Emerald or monomeric Cherry 
fluorescent protein and the protein of interest. HEK293F cells (ThermoFisher Scientific) 
were grown in suspension in FreeStyle™ 293 expression medium. Cells (107 at a density 
of 106 cells/ml) were transfected using a mixture 10 μg of plasmid and 30 μg of 
Polyethylenimine HCl MAX, Mw 40,000 (Polysciences, Inc) (Longo et al., 2013). Two 
days after transfection, ~ 5 x 106 cells were spun, washed once with Hank’s Balanced 
Salt Solution (HBSS) and resuspended into HBSS supplemented with 1% (v/v) of fetal 
bovine serum and 10 mM Na-HEPES pH 7.5 to a final density of 5 x 105 cells/ml and 
briefly vortexed. Cell aggregation was initiated by mixing equal amount of cells into a 
microcentrifuge tube (final volume 1 ml) and incubated at room temperature with 
constant agitation. After a 45-minute incubation, a 0.5-ml aliquot of the reaction was 
transferred to a poly-D-lysine coated glass coverslip. Cells were allowed to attach for 20 
minutes. The cell suspension was then removed and the coverslip was washed once with 
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PBS. Cells were fixed with 4% (w/v) PFA, washed with PBS and mounted. Confocal 
images were acquired sequentially on an Olympus BX61WI with appropriate lasers for 
excitation (488 and 543 nm) and filters (502-538BP and 604-644BP respectively) using 
a DP30BW cooled ccd camera. Images were processed for publication using Fiji 
(Schindelin et al., 2012) 
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crystal structure determination of CNTN1(FN1-FN3), CNTN6(FN1-FN3), CNTN3(Ig5-
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expression, purification and sample preparation for SAXS experiments for CNTN3(FN1-
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CHAPTER 3 
STRUCTURAL BASIS FOR THE CONSERVED INTERACTION OF CNTN3, 4, 5, 
AND 6 WITH THE CA DOMAIN OF PTPRG 
Overview 
Interactions between CAMs at the surfaces of neural cells are essential to guide 
the development and maintenance of the nervous system. Previously, the results of in 
vitro affinity isolation assays have shown that CNTN family members bind to PTPRG 
and PTPRZ (Bouyain and Watkins, 2010). PTPRZ specifically interacts with CNTN1, 
whereas PTPRG binds to CNTN3-6. The binding sites encompass the CA domain of 
PTPRG or PTPRZ and domains Ig2 and Ig3 in CNTNs. The analysis of the crystal 
structures of the PTPRG(CA)•CNTN4(Ig1-Ig4) and PTPRZ(CA)•CNTN1(Ig2-Ig3) 
complexes has provided a structural basis for the interactions between PTPRG/Z and 
CNTNs and confirmed the results of the affinity isolation assays. In particular, these 
structural data indicate a conserved orientation of the protein molecules within the 
complexes in which the β-hairpin loop of PTPRG/Z interacts with a horseshoe-like 
structure formed by repeats Ig2-Ig3 of a CNTN molecule. Despite a similar orientation, 
binding interfaces in these complexes are not the same, with predominantly hydrophobic 
interactions in the PTPRZ(CA)•CNTN1(Ig2-Ig3) complex compared to more polar 
interactions in the PTPRG(CA)•CNTN4(Ig1-Ig4) complex (Bouyain and Watkins, 2010; 
Lamprianou et al., 2011).  
Whereas the binding of CNTN1 and PTPRZ has been demonstrated at the 
surfaces of neurons and glial cells and has been linked to the maturation and 
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differentiation of oligodendrocytes, the in vivo associations of CNTNs with PTPRG has 
yet to be confirmed. Here, I present data that confirm the specific interactions of CNTN3-
6 and PTPRG at the surfaces of HEK293 cells. These data are complemented with 
structural and biochemical studies of PTPRG•CNTN complexes that suggest a conserved 
mode of interactions of PTPRG with CNTN3, 4, 5 and 6 with similar binding affinities. 
Specific interaction of CNTN3-6 with PTPRG on cell surfaces 
To test that PTPRG interacts with CNTN3-6 on cells surfaces, we used HEK293 
cells transfected with full-length hGH-tagged CNTNs and incubated them with the CA 
and FN domains of PTPRG expressed as fusion proteins with human IgG Fc (Fig. 8). In 
agreement with previous affinity-isolation assays PTPRG-Fc fusion proteins bound to 
cells expressing CNTN3-6, but not to cells expressing CNTN1 and 2 (Bouyain and 
Watkins, 2010). These results demonstrate that the specific interactions of PTPRG with 
CNTN3-6, which has been shown in vitro, also occur at the surface of cells. PTPRG does 
not interact with CNTN1, the specific binding partner of PTPRZ. It also does not bind to 
CNTN2, which has been shown to be involved in homophilic interactions.  The 
configuration of this assay suggests a PTPRG/CNTN interaction in trans, which mimics 
interactions of proteins on opposing membranes, similarly to what has been shown for 
CNTN1 and PTPRZ. However, it does not exclude that the two proteins might interact 
when expressed on the same cell (cis-interactions).  
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Figure 8. PTPRG interacts with CNTN3-6, but not with CNTN1 or CNTN2. 
HEK293 cells transfected with full-length CNTNs fused to human growth hormone 
(hGH) were incubated with an Fc fusion of the CA and FN domains of mouse PTPRG 
labeled with fluorescein isothiocyanate (magenta). CNTN-expressing cells were labeled 
with an antibody conjugated to a green fluorophore. The nuclei were visualized using 
DAPI. 
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Similar biochemical characteristics of PTPRG•CNTN interactions 
Previous data from affinity isolation assays along with the results of cell surface 
binding assays presented here confirm the interactions of PTPRG with CNTN3-6. 
However, neither of these techniques can evaluate a difference in binding affinities to 
PTPRG for each CNTN member. The strict conservation of CNTN3-6 amino acid 
residues involved in the interaction with PTPRG suggests a similar binding mode for 
each complex. However, binding affinities may be affected by other factors independent 
of interactions within a binding site, such as binding geometry, surface potential, 
glycosylation pattern, and conformations of CNTN ectodomains. To investigate the 
affinity of interactions within PTPRG•CNTN complexes, we designed a binding assay 
based on AlphaScreen technology in which a biotinylated form of PTPRG(CA) 
immobilized on a streptavidin-coated donor bead interacts with a full-length CNTN-Fc 
fusion protein bound to a protein A acceptor bead via its Fc tag. Protein-protein 
interactions bring donor and acceptor beads together that allows an emission of a 
luminescent signal after illumination at 680 nm. Under this condition, we have measured 
binding affinities indirectly in a competitive-binding assay, using a soluble form of 
PTPRG(CA) as an inhibitor of interactions between our immobilized proteins.  
The calculated IC50 values overall suggest that PTPRG binds CNTN3-6 with 
similar affinities (Fig. 9A). The strongest interaction was detected for the 
PTPRG•CNTN4 complex (IC50 = 235 nM). The IC50 values measured for the binding of 
PTPRG to CNTN3 and 5 are 428 nM and 327 nM, respectively. The association between 
PTPRG and CNTN6, with an IC50 value of 519 nM, appears to be the weakest one.  These 
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IC50 values are also similar to the corresponding IC50 value of 332 nM for 
PTPRZ•CNTN1 complex (Fig. 10, Table 2). 
The obtained IC50 values reflect the binding affinities measured under conditions 
used in particular binding assays and may not be the most accurate representations of the 
physiological Kd values in the cellular environment. For example, in our assay, we used 
a truncated form of PTPRG and artificially dimeric CNTN-Fc fusion proteins. However, 
we can rely on obtained values to characterize the relative binding affinities within the 
different members of CNTN family under given conditions. Based on ANOVA and 
Tukey analysis the differences between CNTN3-CNTN4, CNTN4-CNTN6 and CNTN5-
CNTN6 affinities are characterized as statistically significant, whereas the CNTN3-
CNTN5, CNTN3-CNTN6, and CNTN4-CNTN5 differences are not (Fig. 9B). It remains 
unclear, however, whether these differences in binding affinities lead to distinct 
physiological outcomes. 
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Figure 9. Interactions between the CA domain of PTPRG with CNTN3-6, as 
determined by an AlphaScreen bead-based competition assay. (A) The ability of 
mouse PTPRG(CA) or bovine CAII (control) to inhibit binding between an Fc fusion of 
full length mouse CNTN3-6 and biotin labeled PTPRG(CA) was assessed over a 
logarithmic dilution series. IC50 values are reported as averages ± standard deviations 
from at least three experiments.  One representative experiment for each series is shown. 
See Table 2 and Appendix for detailed results. (B) One-way ANOVA analysis of the IC50 
values measured in (A).  
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Figure 10. Interactions between the CA domain of PTPRZ with CNTN1, as 
determined by an AlphaScreen bead-based competition assay.  The ability of bovine 
CAII (control) and human PTPRZ(CA) to inhibit the AlphaScreen signal between an Fc 
fusion of full length mouse CNTN1 and biotin-labeled PTPRZ(CA) was assessed over a 
logarithmic dilution series. One representative experiment out of four is shown. 
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TABLE 2 
 
SUMMARY OF DATA ANALYSIS CURVE-FITTING OF ALPHASCREEN  
BEAD-BASED COMPETITION ASSAYS 
 
Inhibitor 
Immobilized 
proteins 
IC50 (nM) 
Standard 
deviation 
(nM) 
Number 
of assays 
PTPRZ(CA) 
PTPRZ(CA) 
CNTN1-Fc 
332 15 4 
PTPRG(CA) 
PTPRG(CA) 
CNTN3-Fc 
428 78 7 
PTPRG(CA) 
PTPRG(CA) 
CNTN4-Fc 
235 65 10 
PTPRG(CA) 
PTPRG(CA) 
CNTN5-Fc 
327 39 5 
PTPRG(CA) 
PTPRG(CA) 
CNTN6-Fc 
519 95 7 
PTPRG(CA) 
H295A+V296A 
PTPRG(CA) 
CNTN4-Fc 
917 112 4 
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A conserved binding mode for the PTPRG•CNTN complex formation 
Given the strict conservation of PTPRG-interacting residues in CNTN3-6, we 
wondered if there were distinct structural features that might account for differences in 
binding affinities. For this reason, we determined co-crystal structures of the Ig2-Ig3 
repeats of CNTN3 and CNTN6 bound to the CA domain of PTPRG. The arrangements 
of the protein molecules in the complexes resembled those determined in the 
PTPRZ•CNTN1 and PTPRG•CNTN4 crystal structures (Fig. 11, 12). In both crystal 
structures, the binding interface includes the β-hairpin loop of the CA domain of PTPRG 
(residues 288-301) that contacts the Ig2-Ig3 repeats of CNTN3 or 6 and the PTPRG(CA) 
short loop (residues 225-229) that interacts only with the Ig3 domain of CNTN.  The 
interface areas for the PTPRG•CNTN3 and PTPRG•CNTN6 complexes are 1,668 Å2 and 
1,446 Å2, respectively, and are comparable to those published for the PTPRZ•CNTN1 
(1,658 Å2) and PTPRG•CNTN4 (1,702 Å2) complexes. The values for the shape 
complementarity coefficients are measured as 0.62 for the PTPRG•CNTN3 complex and 
0.68 for the PTPRG•CNTN6 complex. These values are similar to those for the 
PTPRZ•CNTN1 and PTPRG•CNTN4 complexes (0.68 and 0.67, respectively). 
In broad terms, the interfaces for the PTPRG•CNTN complexes can be 
subdivided into four parts (Fig. 13, 14): (1) a predominantly hydrophobic core site that 
comprises the residues on the base of the PTPRG β-hairpin loop, (2) a short 5-aa loop 
region that contacts residues within the Ig3 domain of CNTN3/6, (3) an antiparallel β-
sheet formed by the β-hairpin loop interacting with an antiparallel three-strand β-sheet of 
Ig2 CNTN3/6, and (4) a tip region of the β-hairpin loop formed by residues Q293-V296. 
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The hydrophobic core site in PTPRG•CNTN3/6 complexes is formed by PTPRG(CA) β-
hairpin loop residues F288, T289, T290 and Y301, and CNTN3/6 residues M222 and 
Y225. Site 2 includes PTPRG residues V225-K229 as well residues E226, P227, K228 
and N306 of CNTN3/6. In particular, PTPRG K229 forms a hydrogen bond with N306 
and a salt bridge with E226 in CNTN3/6. In site 3, two strands of the PTPRG β-hairpin 
loop combine with a three strands antiparallel β-sheet in domain Ig2 of CNTN3/6 to form 
a 5-strand antiparallel β-sheet. It is stabilized by the hydrogen bonds between H295-H300 
in PTPRG and G139-L143 in CNTN3/6. In addition, CNTN3/6 Q138 side chain forms 
two hydrogen bonds with the main chain atoms of V299 and the side chain atoms of E300 
in PTPRG. Unlike sites 1-3 that are conserved in all PTPRG•CNTN structures, the tip of 
the β-hairpin in site 4, which includes Q293-V296 side chains, adopts distinct 
conformations in the PTPRG•CNTN3 and PTPRG•CNTN6 complexes. The only 
invariant contact on this site is the packing of H295 from PTPRG against R129 of 
CNTN3/6. Given the distinct conformations of the β-hairpin loop in PTPRG•CNTN 
complexes, we suggest that this region is flexible and does not play an essential role in 
the protein-protein interactions.  
Overall, the conservation of molecular contacts in the PTPRG complexes with 
CNTN3, 4 and 6 (Fig. 15) is consistent with the comparable IC50 values determined in 
protein-protein binding assays. Although it was not possible to obtain co-crystals of the 
PTPRG•CNTN5 complex, analysis of the crystal structure of unliganded CNTN5(Ig1-
Ig4) indicates that the putative PTPRG-binding site is nearly identical to the one 
discovered in the PTPRG•CNTN4 complex (Fig. 16). Thus, the structural information 
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and protein-protein binding assays it can be argued that the mode of PTPRG binding to 
CNTN3, 4, 5 and 6 is conserved. 
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TABLE 3 
 
DATA COLLECTION AND REFINEMENT STATISTICS FOR 
PTPRG(CA)•CNTN3/6 (IG2-IG3) COMPLEXES, AND CNTN5(IG1-IG4) CRYSTAL 
STRUCTURES 
 
 CNTN3(Ig2-Ig3)• 
PTPRG(CA) 
CNTN6(Ig2-Ig3)• 
PTPRG(CA) 
CNTN5(Ig1-Ig4) 
Data Collection       
Beamline APS 22-ID APS 22-BM APS 22-BM 
Wavelength (Å) 1 1 1 
Unique reflections 31,166 70,482 14,070 
Resolution (Å) 50 - 2.6 50 - 2.0 50 - 2.6 
Space group P21212 P212121 C2 
Unit cell       
a, b, c (Å) 
74.14, 78.64,  179.98,  
90.53, 113.53,  50.66,  
147.45 117.05 51.02 
α, β, γ (º) 
90.0,  90.0,  90.0,  
90.0,  90.0,  101.67,  
90 90 90 
Rsym
a 0.134 (0.588)b 0.096 (0.593) 0.154 (0.435) 
Completenessb (%) 99.6 (96.3) 98.7 (89.2) 98.8 (90.7) 
Redundancy 11.4 (5.3) 7.1 (5.3) 6.5 (3.5) 
I/σI 7.2 (2.3) 19.5 (2.0) 11.4 (2.3) 
Refinement       
Molecules  
2 x 2 2 x 2 1 in the asymmetric 
unit 
Resolution (Å) 49.2 - 2.6 24.9 - 2.0 37.0 - 2.6 
Rwork
c / Rfree 0.187/0.249 0.167/0.217 0.195/0.264 
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“TABLE 3 -- Continued.” 
 
DATA COLLECTION AND REFINEMENT STATISTICS FOR 
PTPRG(CA)•CNTN3/6 (IG2-IG3) COMPLEXES, AND CNTN5(IG1-IG4) CRYSTAL 
STRUCTURES 
 
 
CNTN3(Ig2-Ig3)• 
PTPRG(CA) 
CNTN6(Ig2-Ig3)• 
PTPRG(CA) 
CNTN5 
(Ig1-Ig4) 
Refinement    
Number of atoms 7,291 8,039 3,086 
Protein 7,205 7,392 2,968 
Ligand 27 112 28 
Water 59 535 90 
    
R.m.s. deviations    
Ideal bonds (Å) 0.009 0.007 0.003 
Ideal angles (°) 1.1 1.05 0.83 
Average B factors 
(Å2) 71.2 40.9 50.1 
Protein 71.3 40.4 49.6 
Ligand 98.3 71.9 88 
Water 49.9 41.6 51.6 
Ramachandran 
statistics 
   
Favored (%) 94 97 95 
Allowed (%) 6 3 5 
PDB accession code 
5E5R 5E5U 5E4I 
 
aRsym = Σh Σi|Ii(h) - <I(h)>| / Σh Σi Ii(h), where Ii(h) is the ith measurement of reflection 
h and <I(h)> is a weighted mean of all measurements of h. 
bValues in parentheses apply to the high-resolution shell. 
cR = Σh|Fobs(h) – Fcalc(h)| / Σh|Fobs|. Rwork and Rfree were calculated from the working and 
test reflection sets, respectively. The test set constituted 5% of the total reflections not 
used in refinement. 
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Figure 11. The crystal structures of the PTPRG•CNTN3 and PTPRG•CNTN6 
complexes. The PTPRG•CNTN3 (A) and PTPRG•CNTN6 (B) complexes are shown in 
ribbon diagrams along with an overlay of all the complexes formed by PTPRG, PTPRZ 
and their CNTN-binding partners. PTPRG and PTPRZ are colored cyan and green, 
respectively. CNTN3 and CNTN6 are colored in orange and dark green, respectively. 
The letters N and C indicate the N- and C termini, respectively. 
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Figure 12. A conserved arrangement of complexes formed by PTPRG/Z and 
CNTNs. The complexes were superimposed by fitting domains Ig2-Ig3 of CNTN4 with 
the homologous repeats in CNTN1 (RMSD 1.27 Å over 186 equivalent Cαs), CNTN3 
(RMSD 0.97 Å over 180 equivalent Cαs), and CNTN6 (RMSD 1.16 Å over 195 
equivalent Cαs). PTPRG and PTPRZ are colored cyan and green, respectively. CNTN1, 
CNTN3, CNTN4, and CNTN6 are colored slate, magenta, orange and dark green, 
respectively. The letters N and C indicate the N- and C-termini, respectively. 
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Figure 13. The molecular interfaces in PTPRG•CNTN3 and PTPRG•CNTN6 
complexes include four sites of interactions. An “open book” surface representation of 
the binding interfaces for the PTPRG•CNTN3 (A) and PTPRG•CNTN6 (B) complexes. 
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Figure 14. The molecular contacts at PTPRG•CNTN3 and PTPRG•CNTN6 
interfaces. Detailed ribbon diagrams of the binding interfaces for PTPRG•CNTN3 (A) 
and PTPRG•CNTN6 (B) complexes. The contacting residues are shown in ball-and-
sticks representation. These views are in the same orientations as the ones shown on the 
left in Figure 11. Transparent gray spheres highlight residues involved in van der Waals 
contacts. Dashed lines indicate potential hydrogen bonds (black) and salt bridges (green). 
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Figure 15. The PTPRG•CNTN interfaces include essentially identical interactions.  
PTPRG and CNTN3, 4, and 6 are colored cyan, magenta, orange and dark green, 
respectively. Interfaces are shown as ribbon diagrams with the contacting residues shown 
in ball-and-sticks representation.  
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Figure 16. The structure of mouse CNTN5(Ig1-Ig4).  (A) The ribbon diagram of 
mouse CNTN5(Ig1-Ig4) is shown in red overlaid on the crystal structure of mouse 
CNTN4(Ig1-Ig4). The letters N and C indicate the N- and C-termini, respectively. (B) 
Overlay of the PTPRG-binding region of mouse CNTN4 (orange) and mouse CNTN5 
(red). 
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Validation of the PTPRG•CNTN interface 
Most of the interactions in the PTPRG•CNTN complexes involve residues from 
the PTPRG β-hairpin loop. However, the conformational flexibility of its tip suggests 
that this particular region might not be responsible for essential interactions. In order to 
determine the contribution of the different PTPRG regions to interactions with CNTNs, 
we designed three mutant forms of the CA domain of mouse PTPRG: (1) a deletion 
mutant in which residues 290-299 of the β-hairpin loop replaced by the tripeptide ASA, 
(2) a double mutant form with H295A+V296A mutations at the tip of the β-hairpin, and 
(3) another double mutant form with the substitution of H226 and K229 in the short loop 
to alanine (H226A + K229A) (Fig. 17A). These mutant forms were used as inhibitors in 
a competitive binding assay based on Alpha Technology (Fig. 6). All proteins behaved 
comparably to wild-type PTPRG(CA) and in particular are monomeric as determined by 
size exclusion chromatography, which indicates that the mutations did not alter their 
structures. Because the work accomplished so far indicates that PTPRG and CNTNs 
share a conserved binding mode, note that the mutants were only tested in the context of 
the PTPRG•CNTN4 complex.  
The β-hairpin deletion mutant, which eliminates sites 3 and 4, does not inhibit 
interactions between PTPRG and CNTN4, indicating that this region is essential for 
complex formation. However, the PTPRG double mutant with H295A and V296A 
mutations at the tip of the β-hairpin loop inhibits the complex formation with a ~ 4-fold 
increase in IC50 compared to the wild type PTPRG inhibitor (Fig. 17B, Table 2). The 
decrease in the inhibitor binding affinity to CNTN4 may be explained by the disruption 
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of the interactions between hydrophobic V296 of PTPRG and CNTN L142 and V132. 
The mutation of the H295 residue to alanine prevents its interaction with CNTN R129 
and C144. However, the substitution of H295 and V296 to alanine is not expected to 
disrupt the formation of the five-strand antiparallel β-sheet in the complex that preserves 
the most of the mutant’s inhibitory effect.  Finally, mutation of H226 and K229 to alanine 
abrogates the CNTN4-binding activity suggesting that these residues in site 2 mediate 
essential interactions with CNTN4. Indeed, H226 mediates conserved non-polar 
interactions with Y225, P227 and K228, and a hydrogen bond with the main-chain 
oxygen atom of E298. In addition, the K229A mutation disrupts the K229-E226 salt 
bridge and the K229-N306 hydrogen bond. Thus, our interface validation confirms the 
essential role of the PTPRG β-hairpin loop in the PTPRG interactions with CNTN. 
Furthermore, it suggests the important contribution of the small loop of the CA domain 
of PTPRG in complex formation. Although the flexible tip of the PTPRG β-hairpin 
appears to be less critical for the interaction, it still contributes to the binding of PTPRG 
to CNTNs.  
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Figure 17. Mutational analysis of interactions between the CA domain of PTPRG 
with CNTN4. (A) The localization of the introduced mutations against the 4 binding 
sites on the surface of PTPRG(CA). (B) The ability of bovine CAII (control), mouse 
PTPRG(CA) or mouse PTPRG(CA) mutants to inhibit binding between an IgG Fc fusion 
of mouse CNTN4 and a biotin-labeled PTPRG(CA) as it was assessed over a logarithmic 
dilution series. 
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Identification of a PTPRG•CNTN complex in adult mouse retina 
Although our data strongly suggest that PTPRG interacts specifically with 
CNTN3-6 in vitro and at the surfaces of cells (Fig. 8), the in vivo formation of these 
complexes has not been thoroughly investigated yet and is crucial for the validation of 
its physiological relevance.  According to previous studies, both PTPRG and CNTN3-5 
are expressed in specific layers of vertebrate retinas (Horvat-Bröcker et al., 2008; 
Yamagata and Sanes, 2012) although it unknown whether they form a complex in this 
tissue. The retina is an extension of the central nervous system (CNS) that combines 
anatomical and physiological features found in brain and spinal cord (London et al., 
2013). It is also convenient for manipulation and imaging, and therefore is a good model 
for investigation of in vivo protein-protein interactions in nervous tissue. Therefore, we 
focused on the mouse retina to investigate the potential for formation PTPRG•CNTN 
complex formation and to further examine their physiological roles in vivo.  
The retina includes three major neuronal layers (Fig. 18A). Light is first detected 
by photopigments in the outer segments of rod and cone photoreceptor cells spanning the 
outer segment (OS), inner segment (IS) and outer nuclear layer (ONL). Information is 
then transmitted to the bipolar cells found in the inner nuclear layer (INL) and then to 
ganglion cells in the ganglion cell layer (GCL) before being sent to the visual cortex by 
the optic nerve. The outer plexiform layer (OPL) and inner plexiform layer (IPL) include 
synapses between the photoreceptors and bipolar cells and between the bipolar cells and 
ganglion cells, respectively. 
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As a first step, we decided to characterize the distribution of PTPRG and CNTN3 
in an adult mouse retina using immunohistochemistry approach with commercial 
antibodies that had been previously validated in our laboratory (Fig. 21). We detected a 
strong signal for PTPRG in the outer segments (OS), inner segments (IS), inner plexiform 
layer (IPL), and ganglion cell layer (GCL) that is consistent with previous findings 
(Horvat-Bröcker et al., 2008). In contrast to PTPRG, CNTN3 localizes only to the OS 
where it overlaps with PTPRG (Fig. 18B). Despite the co-localization of PTPRG and 
CNTN3 in the OS, it was unclear whether these two proteins form complexes in this 
layer. To address this question, we used an in situ proximity ligation assay (PLA) 
(Söderberg et al., 2008; Hayashi et al., 2013). This type of assay makes it possible to 
visualize in vivo interactions of endogenous PTPRG and CNTN3 with a signal produced 
only if these proteins are less than 40 nm apart. The data suggest that PTPRG and CNTN3 
associate in the retinal OS, which is in line with the co-localization data in the same 
region of retina (Fig. 19). No signal could be observed in control experiments that lack 
the primary antibodies against PTPRG and CNTN3 (Fig. 18B). Moreover, a similar PLA 
signal was observed with a distinct PTPRG antibody raised against its CA domain (Fig. 
22). The sum of these experiments strongly suggests that PTPRG and CNTN3 form a 
complex in the OS of the adult mouse retina.  
Although our data have shown that PTPRG and CNTN3 interact on the surfaces 
of photoreceptors, it was still unclear whether these proteins could form a complex on 
the same photoreceptor (cis-interactions). Previous studies suggest that certain RPTPs 
are able to form functional cis-oriented complexes on the surface of the same cell. For 
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example, Dlar presynaptically binds the heparan sulfate proteoglycan (HSPG) Syndecan 
in cis to promote the formation of synaptic boutons at neuromuscular junctions in 
Drosophila (Johnson et al., 2006). In a similar fashion, PTPRS (vertebrate homolog of 
Dlar) interacts with HSPGs on the surface of the same neural cell to promote axon 
outgrowth (Coles et al., 2011).  
To investigate the potential for cis-interactions between PTPRG and CNTN3, rod 
photoreceptor cells were isolated and dissociated for in situ PLAs. The PLA signal was 
observed in the OS of a single rod cell and is thus consistent with a same-cell interaction 
for PTPRG and CNTN3 in the OS (Fig. 20). Therefore, we can postulate that PTPRG 
and CNTN3 are capable of forming cis complexes in the OS of an adult mouse retina. 
Given the conserved mode of PTPRG•CNTN interactions and overall high sequence 
homology of CNTN members, it is likely that PTPRG and CNTN3-6 interact in cis in 
vivo.  
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Figure 18. PTPRG and CNTN3 are localized to the outer segment of retina. (A) Schematic representation of the retinal 
architecture. Light information detected in an outer segment (OS) of a photoreceptor cell is eventually transmitted to cells in 
the ganglion cell layer (GCL) before being sent to the visual cortex by the optic nerve. (B) PTPRG and CNTN3 both localize 
to the outer segments of adult mouse retinas. A retinal section was stained with antibodies against PTPRG or CNTN3. 
RedDot™ 1 staining was used to visualize nuclei. The panel with DIC (differential interference contrast) shows a more detailed 
view of the retinal organization. Scale bar is 10 μm. 
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Figure 19. PTPRG and CNTN3 associate in the outer segments of photoreceptors. 
A proximity ligation assay (PLA) was performed to detect the presence of a 
PTPRG•CNTN3 complex. Omission of the primary antibodies against PTPRG or 
CNTN3 did not yield any detectable signal (control, left panels) whereas introducing 
these antibodies revealed the presence of punctate staining indicative of PTPRG and 
CNTN3 being in close proximity in the OS. Scale bar is 10 μm. 
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Figure 20. PTPRG and CNTN3 form a cis complex on the outer segment of a 
photoreceptor. An in situ PLA performed on a single photoreceptor cell shows the 
presence of PTPRG•CNTN3 complexes on the same cell. Scale bar is 5 μm. 
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Figure 21. Identification of the PTPRG and CNTN3 complex in the outer segment: 
antibody validation. (A) The rabbit anti-PTPRG antibody used for the experiments 
shown in Figures 18-20 stains the outer segment of an isolated mouse rod cell from a 
wild-type mouse, but not the outer segment of a rod cell from a PTPRG-null mouse. 
Nuclei (blue) were visualized using RedDot™ 1 staining while PTPRG staining is shown 
in green. Scale bars are 5 μm. (B) Validation of anti-CNTN3 antibody (used in 
experiments shown in Fig. 18-20) reveals its specificity against CNTN3, but not against 
other CNTNs.  
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Figure 22. PTPRG•CNTN3 complex formation in the outer segment as reproduced 
with a different anti-PTPRG antibody. An in situ PLA shows that PTPRG and CNTN3 
associate in the outer segments. This experiment includes the same goat anti-CNTN3 
antibody used for the experiments shown in Figures 18-20, whereas PTPRG is detected 
with a rabbit polyclonal antibody raised against its CA domain. Scale bar is 10 μm. 
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PTPRG binds CNTN3 in trans 
The discovery of cis PTPRG•CNTN3 complexes did not exclude the possibility 
that PTPRG and CNTN3 might interact in trans. We decided to investigate this issue by 
designing a cell aggregation assay in which HEK293F cells were transfected either with 
mEmerald-CNTN1, mEmerald-CNTN3, or mCherry-PTPRG. Cells were then mixed 
together and tested for the formation of aggregates.  Cells expressing CNTN1, CNTN3 
or PTRPG only were not able to form aggregates. However, when mixed together, 
PTPRG and CNTN3-expressing cells formed clusters composed of red and green colored 
cells, indicating the presence of the trans cell-adhesion interactions between PTPRG and 
CNTN3 (Fig. 23). The formation of aggregates did not occur in CNTN1 and PTPRG- 
expressing cells, consistent with the inability of PTPRG to bind CNTN1, as shown in our 
previous assays. Thus, our data suggest that in vivo interactions of PTPRG with CNTN3 
occur in both cis and trans configurations, which also may be the case for CNTN4, 5 and 
6.
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Figure 23. PTPRG and CNTN3 interact in trans on the cell surface. The ability of 
PTPRG and CNTN3 to interact in trans was assessed using a cell aggregation assay.  (A-
C) HEK293F cells grown in suspension were transfected with mEmerald-CNTN1, 
mEmerald-CNTN3 or mCherry-PTPRG.  Cells expressing CNTN1, CNTN3 or PTPRG 
alone do not form aggregates.  Likewise, cellular aggregates do not form when CNTN1 
and PTPRG expressing cells are mixed, consistent with the inability of PTPRG and 
CNTN1 to interact with one another (D).  (E) CNTN3 and PTPRG-expressing cells form 
aggregates (white arrowheads) after the two populations are mixed.  Scale bar is 100 μm.  
(F) Close-up view of the PTPRG-CNTN3 cell aggregate designated by a filled arrowhead 
in panel E.  Scale bar is 10 μm. 
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Conclusions 
In this chapter we have combined cell biology, biochemical and structural 
approaches to characterize PTPRG•CNTN complexes. We have demonstrated the 
binding of PTPRG to the HEK293 cells transfected with CNTN3, 4, 5 and 6, but not to 
cells transfected with CNTN1 or 2, confirming the specific PTPRG•CNTN complex 
formation on cell surfaces. In the protein-protein binding assays, we have discovered that 
PTPRG binds to CNTN3-6 with similar affinities. According to our structural analyses, 
the close IC50 values are consistent with the conserved arrangement observed in 
complexes of PTPRG with CNTN3, 4, and 6. Validation of the binding interface 
confirmed that both the β-hairpin loop and a small loop region are critical for the 
interaction of PTPRG with CNTN. Finally, we present data that identify for the first time 
a complex between PTPRG and CNTN family member in vivo.  Our PLA analysis 
suggests that the PTPRG•CNTN3 complex forms on the surface of the OS of a single 
photoreceptor, whereas our cell aggregation experiments suggest that PTPRG and 
CNTN3 can interact in trans. Taken together, our data suggest that PTPRG and CNTN3-
6 might interact in both cis and trans configurations through a conserved binding 
interface. 
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CHAPTER 4 
STRUCTURAL ANALYSES OF CNTN ECTODOMAINS REVEAL AN 
UNEXPECTED BENT CONFORMATION  
Overview 
In the previous chapter, we have shown that CNTN3, and presumably other 
CNTN members, are likely to associate with PTPRG (PTPRZ in the case of CNTN1) in 
both the cis and trans conformations. However, it is unclear how the conformations of 
the CNTN ectodomains would accommodate such distinct binding modes. PTPRG 
appears to include a ~ 300 amino acid stalk region in between its CA-FN moiety and TM 
region. This stalk does not include any recognizable structural motifs other than N- and 
O-linked glycosylation sites and therefore may be flexible enough to engage CNTNs in 
both cis and trans conformations (Barnea et al., 1993). Although the ectodomains of 
CNTNs do not include such a flexible region, they might still be able to bend easily 
because of the linkers between the Ig and FN domains. For example, structural analyses 
of the extracellular region of PTPRS indicate that it adopts several distinct 
conformations. This extent of this conformational mobility is such that PTPRS forms 
both cis and trans interactions with its cognate ligands during the formation of synapses 
(Coles et al., 2014). On the other hand, another model to explain how CNTN3-6 could 
bind PTPRG in both cis and trans conformations would be that the ectodomains lie 
parallel to the cell surface (Fig. 24).  Such a conformation has already been described for 
the neural cell adhesion molecule NCAM2, which features a sharp bend between two 
membrane proximal domains so that the majority of the receptor lies parallel to the cell 
surface (Kulahin et al., 2011).  Therefore, in this chapter, I present crystallographic data 
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that provide a rationale for the formation of PTPRG•CNTN complexes in both cis and 
trans orientations. These data are confirmed by solution scattering experiments 
performed on an FN1-FN3 region of CNTN3. Overall, our data indicate that CNTNs lie 
parallel to the cell membrane to associate with their ligands in both cis and trans 
conformations.  
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Figure 24. A possible model for the co-existence of cis and trans interactions between 
PTPRG and CNTN3-6. A hypothetical model showing how the conformations of 
PTPRG and CNTN3-6 could accommodate the formation of cis or trans complexes 
without altering the interactions between Ig2-Ig3 of CNTNs and the CA domain of 
PTPRG. 
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The Ig5-FN2 region of CNTN3 adopts an extended conformation 
The results from chapter 3 suggested that CNTN3 forms complexes with PTPRG 
in both cis and trans conformations (Fig. 20, 23). Therefore, to gain insights into the 
geometry of a CNTN3 ectodomain, we undertook structural studies of the region 
excluding the first four Ig domains. Our unpublished data have shown that fragments of 
CNTNs that include the FN4 repeat are either unstable or readily form aggregates. 
Therefore, we limited our investigations to the Ig5-FN3 region of CNTN3. Although we 
were able to crystallize this protein, the crystals failed to diffract (Fig. 25). We thus 
further truncated our protein to only the Ig5-FN2 domains of CNTN3 and were able to 
determine the crystal structure of this region, which adopts an extended conformation 
(Fig. 26).  
The detailed analysis of the molecular contacts between consecutive Ig and FN 
domains did not reveal a significant interface, suggesting a certain degree of flexibility 
in this region. For example, the interface between Ig5 and Ig6 domain includes a salt 
bridge between K471 and D526. D526 is conserved in other CNTNs while K471 is either 
a lysine or an arginine (the residue conservation was assessed throughout human, mouse 
and chicken CNTN1-6). Thus, this salt bridge is likely to occur all CNTNs. This 
interaction is complemented with non-polar interactions between Q420, Q422 in Ig5 and 
L529, P499, respectively, in Ig6. These residues are not conserved in all CNTNs, which 
might indicate the transient nature of these interactions. Two contacts occur at the Ig6-
FN1 interface. A hydrogen bond is formed between the conserved R595 residue and the 
carbonyl oxygen of H625. Another contact includes a hydrophobic residue V513 (V, L 
or I in other CNTNs) that forms a non-polar interaction with the conserved G596. In 
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contrast to the Ig5-Ig6 and Ig6-FN1 interfaces, the FN1-FN2 interface is more 
substantial. It includes the non-polar contacts of conserved P667 and W668 residues on 
FN1 with N731 (conserved in CNTN2-6; replaced by Y in CNTN1) and the conserved 
G732 on FN2. The conservation of the molecular contacts between the interfaces implies 
that the Ig5-FN2 fragments of all CNTNs might adopt an extended conformation similar 
to that observed in the CNTN3(Ig5-FN2) region. It is, however, difficult to predict the 
conformation of this region in solution. Our attempts to obtain solution scattering data 
for the Ig5-FN2 region of CNTN3 were ultimately unsuccessful because of protein 
aggregation. The short interdomain linkers indicate that the extended conformation for 
CNTN3(Ig5-FN2) might persist in solution. However, further experiments need to be 
done to characterize the rigidity of this region. 
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Figure 25. Crystals of mouse CNTN3(Ig5-FN3). Protein crystals were obtained in 2.9 
M NaCl, 0.1 Bis-Tris-HCl pH 5.5 but failed to diffract. 
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Figure 26. The extended conformation of Ig5-FN2 domains of mouse CNTN3. Two 
Ig domains (Ig5 and Ig6) and two FN domains (FN1 and FN2) adopt a linear 
conformation in crystals of mouse CNTN3(Ig5-FN2).  
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The FN1-FN3 domains of CNTNs adopt a conserved bent conformation 
The extended conformation found for the Ig5-FN2 region of CNTN3 was not 
sufficient to explain the co-existence of cis and trans interactions of the CNTN3 
ectodomain with PTPRG. Therefore, we determined the crystal structure of the FN1-FN3 
region for CNTN3. Strikingly, this region adopts an L-shaped conformation with a sharp 
bend between its FN2 and FN3 domains (Fig. 27). This bent arrangement is not an artifact 
of crystallization because it is observed in the crystal structures of the FN1-FN3 
fragments of CNTN1, 2, 4, 5, and 6.  These proteins obtained from different species 
(mouse, human and chicken) were crystallized in distinct crystal lattices and all feature a 
sharp bend between domains FN2 and FN3. The superposition performed on FN1-FN2 
domains of FN1-FN3 crystal structures for CNTN1-6 reveals a similar conformation in 
CNTN1-4 and some domain flexibility in the case of CNTN5 and CNTN6 (Fig. 28). 
These fluctuations likely result from the interactions with a symmetry related protein 
chain for the CNTN5 structure, or with another protomer in the same asymmetric unit for 
the CNTN6 structure. The sequence analysis of the FN2-FN3 linker indicates that it is 
fully conserved in CNTN2-4, but reveals some sequence variations in CNTN1, 5 and 6 
(Fig. 29B).  
The analysis of the interface between the FN2 and FN3 domains reveals a similar, 
yet variable mode of interactions for CNTN1-6.  Here, one or two negatively charged 
amino acid residues from the linker region on the FN2 side forms hydrogen bonds with 
a conserved NXA (X = S, T, G, R) region on the FN3 domain (Fig. 29). Other regions 
that contact the FN2-FN3 linker include a glycine-rich stretch on the FN2 domain and a 
positively charged amino-acid residue on the FN3 domain, but these interactions vary 
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among the six CNTNs (Fig. 30). Although not being fully conserved, the linker 
arrangements and FN2-FN3 molecular contacts form similar L-shaped conformations for 
all CNTN members (Fig. 27). The analysis of the FN1-FN2 interface in the FN1-FN3 
crystal structures of CNTNs recapitulates our findings from the CNTN3(Ig5-FN2) crystal 
structure. The non-polar FN1-FN2 interface contacts discovered in CNTN3 are 
conserved in CNTN1, 2, 4, 5 and 6.  Given the conservation of the FN1-FN2 interface 
throughout CNTN1-6 in FN1-FN3 structures, we suggest that this region is relatively 
rigid and does not significantly contribute to the flexibility of CNTN ectodomains.  
 
. 
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TABLE 4 
 
DATA COLLECTION AND REFINEMENT STATISTICS FOR FN1-FN3 DOMAINS OF CNTN1-6 AND IG5-FN2  
DOMAINS OF CNTN3 
 
  CNTN1 
(FN1-FN3) 
CNTN2 
(FN1-FN3) 
CNTN3 
(FN1-FN3) 
CNTN4 
(FN1-FN3) 
CNTN5 
(FN1-FN3) 
CNTN6 
(FN1-FN3) 
CNTN3 
(Ig5-FN2) 
Data 
Collection 
              
Beamline APS 22-ID APS 22-ID APS 22-ID APS 22-BM APS 22-ID APS 22-ID APS 22-BM 
Wavelength 
(Å) 
1 1 1 0.97933 1 1 1 
Unique 
reflections 
48,701 28,357 8,976 13,387 14,285 21,656 20,578 
Resolution 
(Å) 
50 - 2.5 30 - 2.0 50 - 2.8 50 - 2.5 50-2.7 50 - 2.7 50 - 2.4 
Space group P21 P21212 C2 C2221 C2221 P212121 P212121 
Unit cell               
a, b, c (Å) 
87.48  124.39 185.10  94.79  83.77  86.74  58.22 
49.87  40.67  39.03  144.3  154.52  90.85  76.93 
163.3 82.6 52.4 55.4 90.42 99.35 115.82 
α, β, γ (º) 
90.0  90.0  90.0  90.0  90.0  90.0  90.0  
97.12  90.0  96.9  90.0  90.0  90.0  90.0  
90.0 90.0 90.0 90.0 90.0 90.0 90.0 
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“TABLE 4 -- Continued.” 
 
DATA COLLECTION AND REFINEMENT STATISTICS FOR FN1-FN3 DOMAINS OF CNTN1-6 AND IG5-FN2  
DOMAINS OF CNTN3 
 
  CNTN1 
(FN1-FN3) 
CNTN2 
(FN1-FN3) 
CNTN3 
(FN1-FN3) 
CNTN4 
(FN1-FN3) 
CNTN5 
(FN1-FN3) 
CNTN6 
(FN1-FN3) 
CNTN3 
(Ig5-FN2) 
Rsym
a 
0.075 
(0.380) 
0.110 
(0.508) 
0.139 
(0.377) 
0.08      
(0.460) 
0.112 
(0.418) 
0.155 
(0.515) 
0.165    
(0.548) 
Completenessb 
(%) 
99.2 (92.3) 97.8 (89.3) 97.7 (90.0) 98.3 (87.4) 85.7 (56.3) 97.9 (92.5) 98.2 (87.5) 
Redundancy 6.9 (4.7) 5.9 (3.2) 8.9 (5.8) 6.1 (4.2) 12 (5.9) 7.4 (4.8) 11.9 (7.9) 
I/σI 20.4 (3.3) 12.5 (1.6) 15.0 (4) 20.7 (2.3) 17.35 (3.6) 8.4 (2.1) 14.8 (2.4) 
Refinement               
Molecules  
4 1 1 1 1 2 1 in asymmetric 
unit 
Resolution (Å) 43.51 - 2.5 29.1 - 2.0 47.8  - 2.8 28.7 - 2.5 38.6 - 2.7 43.4 - 2.7 43.1 – 2.4 
Rwork
c / Rfree 0.204/0.247 0.190/0.226 0.183/0.244 0.19/0.255 0.194/0.231 0.200/0.241 0.203/0.253 
Number of 
atoms 
9,572 2,491 2,135 2,394 2,282 4,715 3,190 
Protein 9,267 2,301 2,110 2,325 2,258 4,672 3,032 
Ligand 75 - - - 5 - 6 
Water 230 190 25 69 19 43 152 
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“TABLE 4 -- Continued.” 
 
DATA COLLECTION AND REFINEMENT STATISTICS FOR FN1-FN3 DOMAINS OF CNTN1-6 AND IG5-FN2  
DOMAINS OF CNTN3 
 
 
 
CNTN1 
(FN1-FN3) 
CNTN2 
(FN1-FN3) 
CNTN3 
(FN1-FN3) 
CNTN4 
(FN1-FN3) 
CNTN5 
(FN1-FN3) 
CNTN6 
(FN1-FN3) 
CNTN3 
(Ig5-FN2) 
R.m.s. 
deviations 
              
Ideal bonds (Å) 0.004 0.007 0.01 0.009 0.009 0.004 0.009 
Ideal angles (°) 0.84 1.06 1.21 1.12 1.13 0.92 1.28 
Average B  
factors (Å2) 
63.7 39.2 57 61.6 93.7 42.8 41.2 
Protein 63.9 39.1 57.2 61.8 93.8 42.9 41.3 
Ligand 85.5 - - - 121.1 - 62.9 
Water 50.2 40.5 38.9 53.5 69.7 34.9 36.9 
Ramachandran 
statistics 
              
Favored (%) 96 98 95 97 94 97 96 
Allowed (%) 4 2 5 3 6 3 4 
PDB accesion 
code 
 5E53  5E7L  5E4Q  5E4S  5E52  5E55  5I99 
aRsym = Σh Σi|Ii(h) - <I(h)>| / Σh Σi Ii(h), where Ii(h) is the ith measurement of reflection h and <I(h)> is a weighted mean of all 
measurements of h. bValues in parentheses apply to the high-resolution shell.cR = Σh|Fobs(h) – Fcalc(h)| / Σh|Fobs|. Rwork and Rfree 
were calculated from the working and test reflection sets, respectively. The test set constituted 5% of the total reflections not 
used in refinement.
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Figure 27. The FN1-FN3 regions of CNTN family members adopt similar bent 
conformations. Ribbon diagrams of CNTN1-6(FN1-FN3) crystal structures. Residues 
from CNTN1 are colored in slate, from CNTN2 are colored in gray, from CNTN3 are 
colored in magenta, from CNTN4 are colored in orange, from CNTN5 are colored in red 
and from CNTN6 are colored in dark green. 
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Figure 28. Flexibility in the FN3 domain orientation in CNTN1-6 
The FN1-FN2 domains of mouse CNTN2, 3, 4 (A), human CNTN5 (B) and mouse 
CNTN6 (C) were overlaid on the corresponding region of CNTN1.   
Superposition details:  
CNTN1(FN1-FN2)/CNTN2(FN1-FN2) – RMSD: 2.36Å over 188 positions;  
CNTN1(FN1-FN2)/CNTN3(FN1-FN2) – RMSD: 1.15Å over 175 positions;  
CNTN1(FN1-FN2)/CNTN4(FN1-FN2) – RMSD: 2.62Å over 190 positions;  
CNTN1(FN1-FN2)/CNTN5(FN1-FN2) – RMSD: 1.91Å over 189 positions;  
CNTN1(FN1-FN2)/CNTN6(FN1-FN2) – RMSD: 2.00Å over 190 positions. 
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Figure 29. Sequence conservation at the FN2-FN3 interface of CNTNs. (A) 
Conserved amino acid contacts at the FN2-FN3 interface. The structure of CNTN3(FN1-
FN3) is shown as a tube along with a detailed view of the conserved non-covalent 
interactions at the FN2-FN3 interface. Residues at the interface are shown as ball-and-
sticks. Transparent gray spheres and black-dotted lines denote residues involved in van 
der Waals contacts and potential hydrogen bonds, respectively. A more detailed view of 
the FN2-FN3 interface for each CNTN is shown in Figure 30. 
(B) An alignment of mouse CNTN sequences indicates that the contact amino acids at 
the FN2-FN3 interface shown in panel A are conserved in CNTN family members. 
Identical amino acids are shaded in blue while similar residues are colored light gray. 
The numbering corresponds to the mouse CNTN3 sequence. Magenta dots below the 
alignments denote residues at the FN2-FN3 interface. 
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Figure 30. Conserved and specific interactions at the FN2-FN3 interfaces of CNTNs. 
Two-dimensional representations of the contacts at the FN2-FN3 interfaces of CNTNs 
were drawn using LigPlot+ (Laskowski and Swindells, 2011). Dashed lines indicate 
potential hydrogen bonds while spine curves indicate residues involved in hydrophobic 
contacts. Although interactions mediated by the NXA residues found in a loop in FN3 
are conserved in all CNTNs, most contacts at the FN2-FN3 interface are unique to each 
CNTN family member. 
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The bent conformation is conserved in solution 
The results from the previous section indicate that all CNTN FN1-FN3 regions 
adopt a conserved bent arrangement in crystals. Therefore, we surmised that this 
conformation would persist in solution. To test this hypothesis, we analyzed the solution 
conformation of FN1-FN3 of CNTN3 by small angle X-ray scattering. We limited our 
analysis to CNTN3 because our in vivo findings indicate that it forms a cis-complex with 
PTPRG. Data sets were acquired at both different concentrations and exposure times and 
were merged to obtain an experimental scattering profile for CNTN3(FN1-FN3) (Fig. 
31A), which matches closely to the theoretical scattering profile calculated using the 
crystal structure of CNTN3(FN1-FN3) (χ2 = 1.77). Furthermore, the crystal structure of 
CNTN3(FN1-FN3) corresponds a molecular envelope calculated using the experimental 
scattering profile (Fig. 31B). Overall, this analysis demonstrates that the L-shaped 
conformation adopted by this fragment of CNTN3 mirrors its conformation in solution.  
Taken together, these findings indicate that the FN regions of CNTNs all adopt a bent 
conformation reminiscent of the one adopted by NCAM2 (Kulahin et al., 2011).  
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Figure 31. Small-angle X-ray scattering analysis of CNTN3(FN1-FN3). (A) The 
experimental scattering profile (gray) and the theoretical scattering (magenta line, χ2 = 
1.77) calculated from the CNTN3(FN1-FN3) crystal structure. Residuals from the fitting 
of the experimental and scattering profiles are shown below. The lower panel shows the 
Guinier plot with linear fit in red. (B) The crystal structure of CNTN3(FN1-FN3) 
corresponds to a molecular envelope calculated from the experimental solution scattering 
profile CNTN3(FN1-FN3) shown in (A). 
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A model of the PTPRG•CNTN interaction 
Based on the available crystallographic information, we have built a model for 
the conformation of the CNTN ectodomain. First, we superposed the crystal structures 
of CNTN3(Ig5-FN2) and CNTN3(FN1-FN3) to obtain a model for the Ig5-FN3 region 
(Fig. 32). The structure of CNTN3 FN4 has been solved by NMR (PDB ID: 1WJ3) by 
another group. However, we were missing the information about the conformation of the 
linker between the FN3 and FN4 area. Therefore, we have used Modeller 9.15 software 
(Sali and Blundell, 1993) to model this region based on the crystal structure of 
CNTN3(FN1-FN3) and NMR structure of CNTN3FN4. Stereochemical restraints for 
modeling were obtained from the CHARMM-22 molecular mechanics force field 
(Mackerell et al., 1998). The structure with the lowest Modeller 9.15 molpdf score was 
picked.  Given the high sequence similarity of CNTNs, we suggest that the conformation 
of four N-terminal Ig domains of CNTN3 is similar to the one found for the CNTN4(Ig1-
Ig4) structure (PDB ID: 3JXA) (Bouyain and Watkins, 2010).  Because we were missing 
the conformation of the CNTN Ig4-Ig5 linker, we hypothesized that Ig3-Ig5 domains of 
CNTN adopt an extended conformation similar to what has been found in the N-terminal 
regions of NCAM2 (PDB ID: 2WIM) and SYG1 (PDB ID: 4OFY) crystal structures 
(Özkan et al., 2014).  Therefore, to orient the N-terminal horseshoe-like region of CNTN, 
we used the crystal structure of mouse CNTN4(Ig1-Ig4) (PDB ID: 3JXA) as a template, 
and a structure of NCAM2(Ig1-Ig3) to orient the horseshoe-like region against the 
CNTN3(Ig5-FN2) structure. Immunoglobulin domains 3 and 4 of the CNTN4(Ig1-Ig4) 
crystal structure were superposed to Ig1 and Ig2 of NCAM2, and the Ig5 domain of the 
CNTN3(Ig5-FN2) structure was superposed to Ig3 of NCAM2.  The modeled structures 
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of Ig5-FN3, FN1-FN4 and Ig1-FN2 fragments of CNTN3 were then combined to yield a 
hypothetical model of the full-length CNTN3. Given the missing structural information 
for the FN3-FN4 and Ig4-Ig5 linkers, our model can only partially predict the 
conformation of a CNTN ectodomain and we assume that our model might represent 
only a single structure from an array of possible CNTN conformations. We next 
superposed the PTPRG(CA)•CNTN3(Ig2-Ig3) crystal structure on our CNTN3 
ectodomain model to assess the orientation of PTPRG against CNTN. In this case, the 
binding interface of PTPRG and CNTN is oriented in perpendicular to a cell surface (Fig. 
33). Given the flexible spacer region of PTPRG, we suspect that this orientation allows 
both cis and trans interactions without significant conformational changes of both 
molecules.  
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Figure 32. The model of CNTN3(Ig5-FN3) ectodomain. The model was created by the 
superposition of CNTN3(FN1-FN3) and CNTN3(Ig5-FN2) crystal structures 
(RMSD:1.28 Å, over 176 residues).  
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Figure 33. A hypothetical model of the CNTN ectodomain in complex with the CA 
domain of PTPRG. The full-length model of CNTN was built using the CNTN3(Ig5-
FN3) model (Fig. 32), CNTN3FN4 domain (PDB ID: 1WJ3), and a model of 
CNTN4(Ig1-4) domains. The NCAM2(Ig1-Ig3) (PDB ID: 2WIM) model was used to 
orient CNTN4(Ig1-4) structure against the rest of the ectodomain. Modeller was used to 
orient CNTN3FN4 domain. The superposition of the PTPRG(CA)•CNTN3(Ig2-Ig3) 
complex structure was used to model binding of PTPRG(CA) to our CNTN ectodomain 
model.  
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Conclusions 
The data presented in this chapter complement the results described in Chapter 3 
and provide a structural basis for the cis and trans interactions between PTPRG and 
CNTNs. Our results demonstrate that the FN1-FN3 regions of all CNTN family members 
adopt an L-shaped conformation for the FN1-FN3 region with a sharp bend between FN2 
and FN3. This conformation identified in crystals of CNTNs was further confirmed by 
solution scattering experiments performed on CNTN3(FN1-FN3). The crystal structure 
of the CNTN3(Ig5-FN2) region suggests an extended conformation for the portion of 
CNTN ectodomain that follows the FN2-FN3 bend. The modeling of the CNTN 
ectodomain structure suggests that the CNTN ectodomain undergoes sharp bending at 
FN2-FN3 and then extends in parallel to the cell surface. In our model, the binding 
interface of PTPRG•CNTN is oriented perpendicular to the cell surface allowing both a 
cis and trans orientation of the complex.  
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CHAPTER 5 
FINAL DISCUSSION 
A conserved mode of interactions for PTPRG•CNTNs complexes 
In this work, we have used structural, biochemical and cell biological approaches 
to gain insights into the interactions between the receptor protein tyrosine phosphatase 
PTPRG and the neural CAMs CNTN3-6. We have demonstrated that PTPRG specifically 
associates with CNTN3-6 on the cell surface (Fig. 8). It is not uncommon for homologous 
proteins to interact with the same cell surface receptor in the nervous system. However, 
these molecules typically do not bind to the receptor with similar binding affinities. For 
instance, a short splice variant of neurexin – β-neurexin 1 (Nrx1β) specifically binds to 
neuroligins (NL) 1, 2 and 4 during the maturation of glutamatergic and GABAergic 
synapses (Leone et al., 2010). In this case, there is a ~500-fold difference between the 
dissociation constants for these complexes: 16 nM, 8.8 µM, and 115 nM for the 
complexes of β-neurexin 1 with neuroligins-1, 2, and 4, respectively. However, the 
binding affinities measured for the interactions between CNTN3-6 and PTPRG are very 
similar (Fig. 9, Table 2). Moreover, the sum of our structural analyses demonstrates that 
PTPRG binds to CNTN3, 4, 6 – and most likely 5 – in essentially identical fashion.  Thus, 
it remains unclear why four CAMs would bind the same receptor with the same affinity. 
This does not mean, however, that all PTPRG•CNTN complexes are identical. There are 
several ways by which these complexes may be involved in distinct cell signaling events. 
Those possibilities might include: a difference in the localization and timing of protein 
expression; the formation of different multipartite signaling receptors through the 
recruitment of additional binding partners, distinct effects of CNTN binding on the 
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phosphatase activity of PTPRG, or distinct properties of PTPRG•CNTN complexes 
depending on their cis or trans orientation. 
In vivo localization of PTPRG•CNTN complexes 
In broad terms, the expression pattern of CNTN3-6 and PTPRG might look 
similar in the cortical layers and hippocampal cell groups of an adult mouse brain (Lein 
et al., 2007). However, a closer inspection reveals only a partial overlap with some 
differences at the level of specific layers within particular brain structures (Zuko et al., 
2011). The expression patterns of CNTNs are even more complex when observed 
throughout brain development. For example, analysis of the CNTN expression pattern in 
developing mouse cerebellum revealed contacting, but not overlapping zones of CNTN2 
and CNTN6 expression in the deep external granular layer (EGL). The expression of 
CNTN6 starts during the P0 stage of postnatal cerebellum development and replaces 
CNTN2 by stage P15 (Sakurai et al., 2009). Therefore, the expression of PTPRG and 
CNTN within the same brain structure does not necessarily imply that they will associate 
in an active signaling unit. To address this problem, we decided to investigate the 
formation of PTPRG•CNTN complexes by immunofluorescence microscopy of mouse 
tissues.  In particular, we focused on the retina because PTPRG, CNTN3, 4, and 5 are 
expressed in this tissue during development (Yamagata and Sanes, 2012). During the 
course of these investigations, we discovered that PTPRG forms a complex with CNTN3 
in vivo in the outer segment (OS) of adult mouse retinas. We were not able to observe 
similar results for CNTN4 or 5.  In the case of CNTN5, a lack of suitable antibodies 
thwarted our efforts.  In contrast, PTPRG and CNTN4 were not found in similar layers 
of adult retinas and consequently could not associate.  
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Cis-orientation of the PTPRG•CNTN3 complexes  
Our in vivo analysis of the PTPRG•CNTN3 complex has also revealed that these 
two receptors associate on the surface of a single photoreceptor in a cis configuration. 
Given that CNTNs are GPI-anchored proteins and thus lack intracellular regions to 
transmit signals inside the cell, a possible role of their cis interaction with PTPRG could 
be the formation of a co-receptor that interacts with other binding partners. There are in 
fact multiple examples of CNTNs associating in cis with other cell surface receptors (see 
Table 5). 
CNTN1 interacts with a contactin-associated protein 1 (CNTNAP1) in cis, to 
form a co-receptor complex that interacts with neurofascin 155 (NF-155) in paranodal 
junctions (Boyle et al., 2001). These interactions are crucial for paranodal junction 
integrity, proper nerve conduction velocity and distribution of potassium Shaker-type ion 
channels. In another example, CNTN2 binds CNTNAP2 in cis and forms homophilic 
interactions with another CNTN2 molecule in trans at juxtaparanodal junctions (Traka 
et al., 2003). Here, the disruption of the CNTN2/CNTNAP2 tertiary complex in the 
CNTN2 mouse mutant also results in the aberrant localization of CNTNAP2 and Shaker-
type potassium channels but does not significantly affect the functionality of the nerve.  
Recently, CNTN5 has been shown to act as a part of cis CNTN5/CNTNAP4 co-receptor 
complex on the surface of sensory neurons that interacts with Nr-CAM/CHL1 complex 
expressed at the GABAergic interneurons (GABApre) in the mouse spinal cord.  The 
disruption of these interactions results in a partial decrease in the high-density 
accumulation of GABApre boutons on sensory terminals (Ashrafi et al., 2014).  
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Cell adhesion molecules from the the Ig-CAM superfamily are often involved in 
the formation of a co-receptor complex with CNTNs. Neuronal CNTN1 forms a co-
receptor with Nr-CAM, which binds PTPRZ on opposing glial cells (Sakurai et al., 1997). 
These interactions are essential for the promotion of neurite outgrowth and neuronal 
differentiation. CHL1, the member of L1-CAM family, interacts with CNTN6 in cis to 
promote the oriented growth of apical dendrites in the neocortex (Ye et al., 2008). It is 
suggested that the effect of CHL1 and CNTN6 on dendrite outgrowth is mediated through 
PTPRA. 
Another possibility for the formation of cis complexes with CNTNs might 
involve APP/APP-like proteins (Osterfield et al., 2008). The formation of the complex 
in a cis orientation has been shown for CNTN5 and APLP1 at the presynaptic membrane 
of hippocampal neurons (Shimoda et al., 2012). It has been recently demonstrated that 
the interaction of CNTN4 and APP, presumably in a cis orientation, targets axons of 
retinal ganglion cells to the nucleus of the optic tract (Osterhout et al., 2015).  Thus, it is 
not unusual for the members of CNTN family to form co-receptors in a cis orientation, 
as it has been shown for the PTPRG•CNTN3 complex. 
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TABLE 5 
 
PROTEIN-PROTEIN INTERACTIONS OF CONTACTINS 
 
CNTN 
Cis-
partner 
Trans- 
partner 
Localization  
Physiological 
role 
Reference 
CNTN1 
CNTNAP1, 
Kv1 
NF-155 
Paranodal 
junctions 
Paranodal 
junction 
integrity, 
distribution of 
potassium 
shaker-type ion 
channels 
(Boyle et al., 
2001) 
CNTN1 NrCAM PTPRZ 
Neuron-glial 
contacts 
Neuronal 
outgrowth and 
differentiation 
(Sakurai et 
al., 1997) 
CNTN1  
PTPRZ, 
tenascin 
Neuron-glial 
contacts at 
sites of 
myelination 
Differentiation 
of OPCs into 
mature 
oligodendro-
cytes 
(Lamprianou 
et al., 2011) 
CNTN2 
CNTNAP2, 
Kv1 
CNTN2 
Juxta-               
paranodal 
junctions 
Localization of 
CNTNAP2 and 
shaker-type 
potassium 
channels 
(Traka et al., 
2003) 
CNTN4 APP   
RGCs axons 
in accessory 
optic system 
Targeting of 
RGCs axons to 
the nucleus of 
the optic tract 
(Osterhout 
et al., 2015) 
CNTN5 CNTNAP4 
Nr-CAM 
CHL1 
Axoaxonic 
synapses 
between 
sensory 
neurons and 
GABA 
interneurons 
in mouse 
spinal cord 
Accumulation 
of GABApre 
boutons on 
sensory 
terminals 
(Ashrafi et 
al., 2014) 
CNTN6 
PTPRA, 
CHL1 
 
Pyramidal 
neurons of 
neocortex 
Oriented 
growth of 
apical dendrites 
(Ye et al., 
2008) 
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A possible mode of the phosphatase activity regulation 
The discovery of a cis-interaction between PTPRG and CNTN3 suggests a 
possible regulatory effect on the phosphatase activity of PTPRG. It has been mentioned 
previously that tandem phosphatase domains of PTPRG exist in a dimeric conformation, 
which is thought to be inactive in solution (Barr et al., 2009). Therefore, a cis-interaction 
with CNTN3 might modulate the oligomeric state of PTPRG favoring either a 
catalytically active or inactive conformation. For example, the PTN-induced clustering 
of PTPRZ, the close homolog of PTPRG, results in decreased phosphatase activity that 
might be associated with stabilization of the naturally occurring inactive dimeric 
conformation of intracellular phosphatase domains (Fukada et al., 2006). The binding of 
HSPGs to PTPRS stabilizes the phosphatase in an inactive conformation and creates 
zones of increased phosphorylation, whereas the binding of CSPGs has an opposite effect 
on PTPRS activity (Coles et al., 2011). The clustering of PTPRA mediated either by 
CNTN6 or CHL1 leads to increased dephosphorylation of the PTPRA substrate, p59fyn 
kinase, indicating an increase in phosphatase activity (Ye et al., 2008).  
Ligand-induced clustering might also regulate the activity of a receptor 
phosphatase in a concentration-dependent manner. It has been mentioned before that the 
CD45 ectodomain is sterically excluded from the receptor-ligand “close-contact” zones 
during TCR signaling that decreases the effective phosphatase concentration available 
for substrate dephosphorylation (Chang et al., 2016). It can be speculated that a cis 
interaction with CNTN3 might create specific zones with either increased or decreased 
PTPRG phosphatase activity.  
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The model for the cis and trans-interactions  
in PTPRG•CNTN complexes 
The ability of two cell surface receptors expressed on distinct cells (trans 
interactions) to associate with one another is often a critical event triggering signaling 
events that determine cellular fates. Whereas cis interactions between cell surface 
receptors often function to dampen the receptor signaling formed in trans. In addition to 
uncovering cis-interactions between PTPRG and CNTN3, we demonstrated that PTPRG 
and CNTN3 also associate in trans. This is consistent with the trans interaction found in 
PTPRZ•CNTN1 complex (Table 4), which has a similar domain orientation to 
PTPRG•CNTN complexes (Lamprianou et al., 2011). Because of the homology between 
CNTN3-6, we surmise that these four CNTNs are able to associate in cis/trans with 
PTPRG. It was unclear, however, how PTPRG and CNTN3 could form a complex in 
both the cis and trans orientation using the same binding interface. Our structural 
analyses indicate that the CNTN3 ectodomain, and presumably all CNTN ectodomains, 
is oriented parallel to the cell surface to allow both cis and trans orientations. On the 
other hand, our insights into the conformation of the CNTN3 extracellular domain 
provide an explanation of how long CNTN molecules such as CNTNs could be 
accommodated within a narrow space between two opposing cells. As mentioned before, 
CNTN1 is involved in myelination process and localizes at paranodal axon membranes, 
where it acts as an organizer molecule during the formation of axoglial septate-like 
paranodal junctions (Boyle et al., 2001; Çolakoğlu et al., 2014). The intermembrane 
spacing in septate-like paranodal junctions was measured by electron tomography as ~ 
75 Å (Nans et al., 2011). Given an approximate length of a single Ig or FN domain of 
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CNTN measured along the domain axis as ~ 40 Å, the total length of an extended CNTN 
extracellular moiety would be around 320 Å. Indeed, to pack within a narrow space such 
as this one, a long CNTN molecule cannot just simply extend from the cell surface. In 
contrast, the bent conformations of CNTN ectodomains conformation presented in this 
thesis are consistent with their localization within the limited space of paranodal 
junctions. Moreover, CNTN5 and CNTN6 were reported to localize at chemical 
synapses, where the distance between pre- and postsynaptic membranes is around 200 Å 
(Sakurai et al., 2010; Shimoda et al., 2012).  Here, a bent conformation of a CNTN 
molecule localized on a presynaptic membrane might provide additional space to 
accommodate the possible CNTN interactors on a postsynaptic membrane. A similar 
arrangement has been observed for the ectodomain of the synaptic cell adhesion molecule 
NCAM2, which indicates that these folded protein conformations might be a common 
theme in the conformations of neural adhesion molecules (Kulahin et al., 2011). 
It is tempting to speculate that cis and trans orientations of the PTPRG•CNTN 
complexes might be associated with the formation of functionally distinct co-receptors 
(Fig. 34). These complexes might have a differential effect on the phosphatase activity 
as it is in the case of type IIa RPTPs.  For example, PTPRS is activated when binding to 
HSPGs in cis and inhibited when associating with CSPGs in trans. A similar effect has 
been uncovered with the phosphatase LAR in Drosophila (Johnson et al., 2006). The 
binding of Syndecan to LAR in cis activates the cytoplasmic phosphatase activity to 
promote the growth of synaptic boutons.  In contrast, Dally-like protein, expressed on an 
opposing cell, displaces Syndecan in a competitive fashion to inhibit LAR, which results 
in the switch from the growth of synaptic boutons to the assembly of the synaptic active 
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zone (Johnson et al., 2006). The distinct effects that cis and trans might have on receptor 
activity is not limited to RPTPs, however, and have been described in Delta-Notch 
signaling. Here, the canonical trans binding results in the activation of the Notch 
pathway, whereas the formation of the same complex on the same cell surface in cis has 
an inhibitory effect (Matsugo et al., 2015). In this model, Delta-like protein 4 (DLL4) 
forms an antiparallel dimeric complex with Notch1 that is consistent both with the trans 
and cis orientations (Matsugo et al., 2015). For both scenarios, the Delta-Notch complex 
would be oriented in parallel to the cell surface, which is similar to our model of 
PTPRG•CNTN interaction. Importantly, CNTN6 and CNTN1 have been characterized 
as Notch ligands during the differentiation and maturation of oligodendrocytes (Hu et al., 
2003; Cui et al., 2004). The L-shaped conformation of the CNTN ectodomain might thus 
be consistent with both cis and trans association with Notch. Although the mechanism 
of Delta/Notch signaling is completely different from that of RPTP signaling, we surmise 
that a similar scenario might take place for PTPRG and CNTN interactions. 
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Figure 34. A possible model for the formation of PTPRG•CNTN co-receptor 
complexes in cis and trans orientations. PTPRG interacts with CNTN either in cis or 
trans orientation. By recruiting potential binding partners cis and trans PTPRG•CNTN 
co-receptors form tertiary complexes with alternative functionalities.  
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A possible role for PTPRG in photoreceptor outer segments 
The discovery of the PTPRG•CNTN3 complex in the OS of photoreceptors raises 
a question about its physiological role in this region. We might speculate that this role is 
associated with the phosphatase activity of PTPRG. Given the fact that a PTPRG 
substrate has yet to be discovered, it is unclear what the substrates of PTPRG in 
photoreceptors could be. The OS is the region of a photoreceptor that is directly involved 
in phototransduction. The conversion of the light signal in a photoreceptor is performed 
by the G-protein-coupled receptor rhodopsin, which uses the G protein transducin to 
activate phosphodiesterase. This is turn leads to an increased cGMP hydrolysis and a 
closure of cyclic nucleotide-gated (CNG) channels, causing membrane hyperpolarization 
and further signal transduction. The activity of CNG channels is regulated in part by 
binding to Ca2+/calmodulin, diacylglycerol and divalent ions (Kramer and Molokanova, 
2001). One of the most important processes underlying the regulation of CNG channels 
is phosphorylation. The phosphorylation of Y498 on the CNG channel nucleotide-
binding alpha domain results in the channel’s closure due to its decreased affinity to 
cGMP (Molokanova et al., 1997, 1999). The presence of tyrosine phosphorylation as a 
regulatory factor would also indicate some tyrosine dephosphorylation activity that might 
be attributed to intracellular PTPs or RPTPs including PTPRG. It has been shown 
recently that the insulin receptor (IR) directly phosphorylates CNG channels either in a 
light- or insulin-dependent manner (Gupta et al., 2012). Conversely, IGF-1 secreted by 
retinal pigment epithelial cells increases the cGMP sensitivity of CNG channels, 
presumably by recruiting a phosphatase (Savchenko et al., 2001).  Another link between 
the IGF-1 signaling and phosphatase activity in photoreceptors might be associated with 
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the STAT3 transcription factor. During the development of the retina, IGF-1 signaling 
mediates the downstream dephosphorylation of STAT3. This process has been shown to 
involve PKCβ1 and γ, and the non-receptor tyrosine phosphatases Shp1 and Shp2. This 
pathway is thought to be essential for the differentiation of the rod photoreceptors from 
the retinal progenitors (Pinzon-Guzman C, Xing T, Zhang SS, 2011). The increased 
expression of the tyrosine phosphorylated form of STAT3 (pSTAT3) has been also linked 
to photoreceptor survival in murine models of photoreceptor degeneration (Jiang et al., 
2014). Several studies performed in cancer cell lines characterize pSTAT3 as a substrate 
for RPTPs, such as PTPRD, CD45, PTPRT, and PTPRJ (Zhang et al., 2007; Ortiz et al., 
2014; Yan et al., 2015; Kumar et al., 2016). In fact, recent data suggest that STAT3 might 
be activated by PTPRG activity in monocytes (Mirenda et al., 2015). It is tempting to 
speculate that PTPRG might act cooperatively with other receptor phosphatases to ensure 
an adequate balance between the phosphorylated and non-phosphorylated STAT forms 
during the phototransduction or photoreceptor survival. In this regard, the OS of an adult 
mouse retina has been shown to be abundant in different receptor phosphatases, including 
PTPRS, PTPRE, PTPRJ, PTPRK, RPTPRR, as well as PTPRG (Horvat-Bröcker et al., 
2008).  
In the adult retina, the OS constantly renews itself through shedding of the apical 
disk, which is phagocytosed by the retinal pigmented epithelium (Kennedy and Malicki, 
2009). The possible role of RPTPs in this area might include maintenance of proper 
substrate phosphorylation levels in the rapidly growing cell region. Interestingly, the OS 
of each photoreceptor is surrounded by an interphotoreceptor matrix (IPM) enriched with 
growth factors, enzymes and proteoglycans (Ishikawa et al., 2015). Here, the interaction 
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of PTPRG and CNTN3 on the OS membrane might provide an interface for the binding 
of molecules originated from the matrix. For example, similarly to what has been shown 
for PTPRS and LAR receptor phosphatases, proteoglycans of the IPM might be involved 
it the regulation of the phosphatase activity of PTPRG or other RPTPs. The primary 
physiological roles of the interaction between OS and IPM include the OS adhesion to 
RPE, retinoid, oxygen and nutrient transport to photoreceptors, and cytoskeletal 
rearrangements. It has been shown in murine models that components of IPM are 
significant in the etiology of retinal degeneration disorders (Ishikawa et al., 2015).  Any 
of these processes might potentially involve the PTPRG/CNTN3 signaling.  
Given a large number of receptor phosphatases in the OS, it is difficult to imagine 
an exact role for the PTPRG•CNTN complex in this region. PTPRG-null mice show no 
abnormality in retinal laminar organization or in the expression of specific retinal 
markers, suggesting only a minor role of PTPRG during the retinal development, if any. 
In contrast, the PTPRZ-/- mice exhibit decreased expression of vimentin, a marker for 
Müller glial cells, along with an altered morphology of Müller glial cell processes 
(Horvat-Bröcker et al., 2008). It should be noted that the current examinations of retinas 
were performed at a P1 stage and may not reflect the full role of PTPRG and PTPRZ 
during other developmental stages or well into adulthood. 
Because of the lack of distinct anatomical phenotypes for mice deficient in 
PTPRG and CNTN3-6, further experiments should be focused on the detailed 
investigation of functional electrophysiological outputs. For example, removal of CNTN4 
in mice, which affects the ability of the specific subset of retinal ganglion cells to target 
the nucleus of the optic tract, results in a decreased ability to track the horizontal 
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movement of the image (Osterhout et al., 2015). CNTN5 null mice have specific defects 
in the auditory system including abnormal responses to auditory stimuli and specific 
behavioral changes (Li et al., 2003).  In summary, genetic removal of CNTN-encoding 
genes in sensory pathways does not lead to gross defects in sensory organ function, but 
rather appears to alter how the information is processed. These subtle changes might be 
significant at the level of the human brain by producing specific behavioral deviations. 
In fact, mutations in CNTN3-6 genes have been shown to be associated with autism 
spectrum disorders (ASDs) and other neuropsychiatric diseases (Zuko et al., 2011). Thus, 
the role of the PTPRG•CNTN3 complex in the retina should be thoroughly investigated 
in knock-out animals during various developmental stages as well as in the adult animals 
with focus on the processing of specific visual inputs. 
Future directions 
The future directions of this work should be focused on both fundamental and 
clinically relevant research topics.  Therefore, it is important to characterize the 
interactions between PTPRG and CNTN within the context of the existing disorders 
associated with PTPRG, CNTN3-6 or their binding partners, such as CNTNAPs, 
APP/APLP or L1-CAM family members.  
Although we were able to show the formation of the PTPRG•CNTN complex in 
vivo, the exact function and the signaling pathway for this interaction has yet to be 
discovered. It is likely that both proteins act as parts of the larger membrane-associated 
protein complexes, and this should be further investigated. Characterizing these entities 
might shed a light on the functional difference between the cis and trans orientations of 
the PTPRG•CNTN complexes. 
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It is important to establish the relationship between the cell-adhesion created by 
PTPRG and CNTN and the phosphatase activity of PTPRG. For this reason, we need to 
identify substrates specific for PTPRG phosphatase function. It seems likely that that the 
activity of PTPRG in knock-out animals might be rescued by other RPTPs. Therefore, it 
is important to dissect possible overlap in RPTPs functionality by creating relevant 
experimental platforms.  Finally, there are still questions related to the structural aspects 
of interactions of CAMs and RPTPs on the cell surface, such as the relationship between 
the phosphatase signaling and oligomerization.  
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APPENDIX 
 
 DETAILED PARAMETERS OBTAINED FROM DATA ANALYSIS CURVE-FITTING OF  
ALPHASCREEN BEAD-BASED COMPETITION ASSAYS. 
 
Inhibitor 
Immobilized 
proteins 
IC50 (nM) R2 Signal/Noise 
Points 
analyzed 
Outliers 
95% confidence 
interval 
PTPRZ(CA) 
PTPRZ(CA) 
CNTN1-Fc 
353 0.99 1051 20 0 283 to 441 nM 
PTPRZ(CA) 
PTPRZ(CA) 
CNTN1-Fc 
316 0.99 1307 19 0 242 to 413 nM 
PTPRZ(CA) 
PTPRZ(CA) 
CNTN1-Fc 
328 0.98 417 19 0 224 to 481 nM 
PTPRZ(CA) 
PTPRZ(CA) 
CNTN1-Fc 
332 0.93 445 17 2 157 to 705 nM 
PTPRG(CA) 
PTPRG(CA) 
CNTN3-Fc 
306 0.98 994 18 1 224 to 418 nM 
PTPRG(CA) 
PTPRG(CA) 
CNTN3-Fc 
437 0.98 997 19 0 324 to 589 nM 
PTPRG(CA) 
PTPRG(CA) 
CNTN3-Fc 
465 0.99 1019 19 0 372 to 580 nM 
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“APPENDIX -- Continued.” 
 
DETAILED PARAMETERS OBTAINED FROM DATA ANALYSIS CURVE-FITTING OF ALPHASCREEN BEAD-
BASED COMPETITION ASSAYS. 
 
Inhibitor 
Immobilized 
proteins 
IC50 (nM) R2 Signal/Noise Points Outliers 
95% confidence 
interval 
PTPRG(CA) 
 
PTPRG(CA) 
CNTN3-Fc 
418 
 
0.99 
 
1206 
 
18 
 
1 
 
365 to 479 nM 
 
PTPRG(CA) 
PTPRG(CA) 
CNTN3-Fc 
564 0.98 932 19 0 408 to 780 nM 
PTPRG(CA) 
PTPRG(CA) 
CNTN3-Fc 
412 0.99 780 19 0 315 to 538 nM 
PTPRG(CA) 
PTPRG(CA) 
CNTN3-Fc 
397 0.98 621 19 0 282 to 559 nM 
PTPRG(CA) 
PTPRG(CA) 
CNTN4-Fc 
146 0.98 303 19 0 103 to 205 nM 
PTPRG(CA) 
PTPRG(CA) 
CNTN4-Fc 
192 0.98 364 19 0 142 to 259 nM 
PTPRG(CA) 
PTPRG(CA) 
CNTN4-Fc 
207 0.99 605 19 0 173 to 248 nM 
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“APPENDIX -- Continued.” 
 
DETAILED PARAMETERS OBTAINED FROM DATA ANALYSIS CURVE-FITTING OF ALPHASCREEN BEAD-
BASED COMPETITION ASSAYS. 
 
Inhibitor 
Immobilized 
proteins 
IC50 (nM) R2 Signal/Noise Points Outliers 
95% confidence 
interval 
PTPRG(CA) 
PTPRG(CA) 
CNTN4-Fc 
235 0.99 579 19 0 193 to 287 nM 
PTPRG(CA) 
PTPRG(CA) 
CNTN4-Fc 
153 0.96 303 19 0 92 to 254 nM 
PTPRG(CA) 
PTPRG(CA) 
CNTN4-Fc 
236 0.99 729 17 2 202 to 274 nM 
PTPRG(CA) 
PTPRG(CA) 
CNTN4-Fc 
297 0.99 460 19 0 239 to 367 nM 
PTPRG(CA) 
PTPRG(CA) 
CNTN4-Fc 
343 0.98 183 19 0 261 to 451 nM 
PTPRG(CA) 
PTPRG(CA) 
CNTN4-Fc 
236 0.97 350 19 0 187 to 296 nM 
PTPRG(CA) 
PTPRG(CA) 
CNTN4-Fc 
305 0.98 193 19 0 230 to 401 nM 
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“APPENDIX -- Continued.” 
 
DETAILED PARAMETERS OBTAINED FROM DATA ANALYSIS CURVE-FITTING OF ALPHASCREEN BEAD-
BASED COMPETITION ASSAYS. 
 
Inhibitor 
Immobilized 
proteins 
IC50 (nM) R2 Signal/Noise Points Outliers 
95% confidence 
interval 
PTPRG(CA) 
PTPRG(CA) 
CNTN5-Fc 
311 0.99 802 19 0 257 to 377 nM 
PTPRG(CA) 
PTPRG(CA) 
CNTN5-Fc 
298 0.99 1511 19 0 245 to 362 nM 
PTPRG(CA) 
PTPRG(CA) 
CNTN5-Fc 
395 0.98 1334 18 1 288 to 541 nM 
PTPRG(CA) 
PTPRG(CA) 
CNTN5-Fc 
315 0.99 678 19 0 243 to 409 nM 
PTPRG(CA) 
PTPRG(CA) 
CNTN5-Fc 
317 0.98 606 18 1 236 to 426 nM 
PTPRG(CA) 
PTPRG(CA) 
CNTN6-Fc 
397 0.98 289 19 0 287 to 550 nM 
PTPRG(CA) 
PTPRG(CA) 
CNTN6-Fc 
636 0.99 431 17 2 490 to 824 nM 
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“APPENDIX -- Continued.” 
 
DETAILED PARAMETERS OBTAINED FROM DATA ANALYSIS CURVE-FITTING OF ALPHASCREEN BEAD-
BASED COMPETITION ASSAYS. 
 
Inhibitor 
Immobilized 
proteins 
IC50 (nM) R2 Signal/Noise Points Outliers 
95% confidence 
interval 
PTPRG(CA) 
PTPRG(CA) 
CNTN6-Fc 
406 0.98 390 17 2 284 to 579 nM 
PTPRG(CA) 
PTPRG(CA) 
CNTN6-Fc 
563 0.96 332 17 2 327 to 967 nM 
PTPRG(CA) 
PTPRG(CA) 
CNTN6-Fc 
579 0.96 324 17 2 344 to 975 nM 
PTPRG(CA) 
PTPRG(CA) 
CNTN6-Fc 
586 0.99 254 18 1 445 to 771 nM 
PTPRG(CA) 
PTPRG(CA) 
CNTN6-Fc 
465 0.97 43 17 2 315 to 686 nM 
PTPRG(CA) 
H295A + V296A 
PTPRG(CA) 
CNTN4-Fc 
761 0.99 616 17 2 573 to 1,010 nM 
PTPRG(CA) 
H295A + V296A 
PTPRG(CA) 
CNTN4-Fc 
940 0.99 378 19 0 724 to 1,220 nM 
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“APPENDIX -- Continued.” 
 
DETAILED PARAMETERS OBTAINED FROM DATA ANALYSIS CURVE-FITTING OF ALPHASCREEN BEAD-
BASED COMPETITION ASSAYS. 
 
Inhibitor 
Immobilized 
proteins 
IC50 (nM) R2 Signal/Noise Points Outliers 
95% confidence 
interval 
PTPRG(CA) 
H295A + V296A 
PTPRG(CA) 
CNTN4-Fc 
940 0.99 156 19 0 712 to 1,241 nM 
PTPRG(CA) 
H295A + V296A 
PTPRG(CA) 
CNTN4-Fc 
1028 0.97 288 19 0 686 to 1,541 nM 
 
 
 
 
 
  
 
 112 
 
REFERENCES 
 
Adams, P. D.; Afonine, P. V.; Bunkóczi, G.; Chen, V. B.; Davis, I. W.; Echols, N.; 
Headd, J. J.; Hung, L. W.; Kapral, G. J.; Grosse-Kunstleve, R. W.; et al. PHENIX: A 
Comprehensive Python-Based System for Macromolecular Structure Solution. Acta 
Crystallogr. Sect. D Biol. Crystallogr. 2010, 66 (2), 213–221. 
Andersen, J. N.; Jansen, P. G.; Echwald, S. M.; Mortensen, O. H.; Fukada, T.; Del 
Vecchio, R.; Tonks, N. K.; Møller, N. P. H. A Genomic Perspective on Protein Tyrosine 
Phosphatases: Gene Structure, Pseudogenes, and Genetic Disease Linkage. FASEB J. 
2004, 18 (1), 8–30. 
Arévalo, J. C.; Wu, S. H. Neurotrophin Signaling: Many Exciting Surprises! Cell. Mol. 
Life Sci. 2006, 63 (13), 1523–1537. 
Aricescu, A. R.; Lu, W.; Jones, E. Y. A Time- and Cost-Efficient System for High-Level 
Protein Production in Mammalian Cells. Acta Crystallogr. Sect. D Biol. Crystallogr. 
2006, 62 (10), 1243–1250. 
Ashrafi, S.; Betley, J. N.; Comer, J.; Brenner-Morton, S.; Bar, V.; Shimoda, Y.; 
Watanabe, K.; Peles, E.; Jessell, T.; Kaltschmidt, J. Neuronal Ig/Caspr Recognition 
Promotes the Formation of Axoaxonic Synapses in Mouse Spinal Cord. Neuron 2014, 81 
(1), 120–129. 
Barnea, G.; Silvennoinen, O.; Shaanan, B.; Honegger,  a M.; Canoll, P. D.; D’Eustachio, 
P.; Morse, B.; Levy, J. B.; Laforgia, S.; Huebner, K. Identification of a Carbonic 
Anhydrase-like Domain in the Extracellular Region of RPTP Gamma Defines a New 
Subfamily of Receptor Tyrosine Phosphatases. Mol. Cell. Biol. 1993, 13 (3), 1497–1506. 
Barr, A. J.; Ugochukwu, E.; Lee, W. H.; King, O. N. F.; Filippakopoulos, P.; Alfano, I.; 
Savitsky, P.; Burgess-Brown, N. a; Müller, S.; Knapp, S. Large-Scale Structural Analysis 
of the Classical Human Protein Tyrosine Phosphatome. Cell 2009, 136 (2), 352–363. 
Bilwes,  a M.; den Hertog, J.; Hunter, T.; Noel, J. P. Structural Basis for Inhibition of 
Receptor Protein-Tyrosine Phosphatase-Alpha by Dimerization. Nature. 1996, pp 555–
559. 
Blanchetot, C.; Tertoolen, L. G. J.; den Hertog, J. Regulation of Receptor Protein-
Tyrosine Phosphatase Alpha by Oxidative Stress. EMBO J. 2002, 21 (4), 493–503. 
Bouyain, S.; Watkins, D. J. The Protein Tyrosine Phosphatases PTPRZ and PTPRG Bind 
to Distinct Members of the Contactin Family of Neural Recognition Molecules. Proc. 
Natl. Acad. Sci. U. S. A. 2010, 107 (6), 2443–2448. 
Boyle, M. E. T.; Berglund, E. O.; Murai, K. K.; Weber, L.; Peles, E.; Ranscht, B. 
Contactin Orchestrates Assembly of the Septate-like Junctions at the Paranode in 
Myelinated Peripheral Nerve. Neuron 2001, 30 (2), 385–397. 
Burridge, K.; Sastry, S. K.; Sallee, J. L. Regulation of Cell Adhesion by Protein-Tyrosine 
Phosphatases: I. Cell-Matrix Adhesion. J. Biol. Chem. 2006, 281 (23), 15593–15596. 
 113 
 
Canoll, P. D.; Petanceska, S.; Schlessinger, J.; Musacchio, J. M. Three Forms of RPTP-
Beta Are Differentially Expressed during Gliogenesis in the Developing Rat Brain and 
during Glial Cell Differentiation in Culture. J. Neurosci. Res. 1996, 44 (3), 199–215. 
Chang, V. T.; Fernandes, R. A.; Ganzinger, K. A.; Lee, S. F.; Siebold, C.; McColl, J.; 
Jönsson, P.; Palayret, M.; Harlos, K.; Coles, C. H.; et al. Initiation of T Cell Signaling by 
CD45 Segregation at “Close Contacts.” Nat. Immunol. 2016, 17 (5). 
Çolakoğlu, G.; Bergstrom-Tyrberg, U.; Berglund, E. O.; Ranscht, B. Contactin-1 
Regulates Myelination and Nodal/paranodal Domain Organization in the Central 
Nervous System. Proc. Natl. Acad. Sci. U. S. A. 2014, 111, E394–E403. 
Coles, C. H.; Shen, Y.; Tenney, A. P.; Siebold, C.; Sutton, G. C.; Lu, W.; Gallagher, J. 
T.; Jones, E. Y.; Flanagan, J. G.; Aricescu,  a R. Proteoglycan-Specific Molecular Switch 
for RPTPσ Clustering and Neuronal Extension. Science 2011, 332 (6028), 484–488. 
Coles, C. H.; Mitakidis, N.; Zhang, P.; Elegheert, J.; Lu, W.; Stoker, A. W.; Nakagawa, 
T.; Craig, A. M.; Jones, E. Y.; Aricescu,  a R. Structural Basis for Extracellular Cis and 
Trans RPTPσ Signal Competition in Synaptogenesis. Nat. Commun. 2014, 5 (0615), 
5209. 
Cui, X.-Y.; Hu, Q.-D.; Tekaya, M.; Shimoda, Y.; Ang, B.-T.; Nie, D.-Y.; Sun, L.; Hu, 
W.-P.; Karsak, M.; Duka, T.; et al. NB-3/Notch1 Pathway via Deltex1 Promotes Neural 
Progenitor Cell Differentiation into Oligodendrocytes. J. Biol. Chem. 2004, 279 (24), 
25858–25865. 
Desai, D. M.; Sap, J.; Schlessinger, J.; Weiss,  a. Ligand-Mediated Negative Regulation 
of a Chimeric Transmembrane Receptor Tyrosine Phosphatase. Cell 1993, 73 (3), 541–
554. 
Emsley, P.; Cowtan, K. Coot: Model-Building Tools for Molecular Graphics. Acta 
Crystallogr. Sect. D Biol. Crystallogr. 2004, 60 (12 I), 2126–2132. 
Franke, D.; Svergun, D. I. DAMMIF , a Program for Rapid Ab-Initio Shape 
Determination in Small-Angle Scattering. J. Appl. Crystallogr. 2009, 42 (2), 342–346. 
Fukada, M.; Fujikawa, A.; Chow, J. P. H.; Ikematsu, S.; Sakuma, S.; Noda, M. Protein 
Tyrosine Phosphatase Receptor Type Z Is Inactivated by Ligand-Induced 
Oligomerization. FEBS Lett. 2006, 580 (17), 4051–4056. 
Guinier, A.; Fournet, G. Small Angle Scattering of X-Rays. Journal of Polymer Science. 
1956, pp 594–594. 
Gupta, V. K.; Rajala, A.; Rajala, R. V. S. Insulin Receptor Regulates Photoreceptor CNG 
Channel Activity. Am. J. Physiol. Endocrinol. Metab. 2012, 303 (11), E1363–E1372. 
Hamaoka, B. Y.; Dann, C. E.; Geisbrecht, B. V; Leahy, D. J. Crystal Structure of 
Caenorhabditis Elegans HER-1 and Characterization of the Interaction between HER-1 
and TRA-2A. Proc. Natl. Acad. Sci. U. S. A. 2004, 101 (32), 11673–11678. 
Harroch, S.; Furtado, G. C.; Brueck, W.; Rosenbluth, J.; Lafaille, J.; Chao, M.; Buxbaum, 
J. D.; Schlessinger, J. A Critical Role for the Protein Tyrosine Phosphatase Receptor 
 114 
 
Type Z in Functional Recovery from Demyelinating Lesions. Nat. Genet. 2002, 32 (3), 
411–414. 
Hasegawa, H.; Holm, L. Advances and Pitfalls of Protein Structural Alignment. Curr. 
Opin. Struct. Biol. 2009, 19 (3), 341–348. 
Hayashi, M.; Majumdar, A.; Li, X.; Adler, J.; Sun, Z.; Vertuani, S.; Hellberg, C.; 
Mellberg, S.; Koch, S.; Dimberg, A.; et al. VE-PTP Regulates VEGFR2 Activity in Stalk 
Cells to Establish Endothelial Cell Polarity and Lumen Formation. Nat. Commun. 2013, 
4, 1672. 
Hayashi, N.; Miyata, S.; Yamada, M.; Kamei, K.; Oohira,  a. Neuronal Expression of the 
Chondroitin Sulfate Proteoglycans Receptor-Type Protein-Tyrosine Phosphatase β and 
Phosphacan. Neuroscience 2005, 131 (2), 331–348. 
Hermiston, M. L.; Xu, Z.; Weiss, A. CD45: A Critical Regulator of Signaling Thresholds 
in Immune Cells. Annu. Rev. Immunol. 2003, 21, 107–137. 
Horvat-Bröcker, A.; Reinhard, J.; Illes, S.; Paech, T.; Zoidl, G.; Harroch, S.; Distler, C.; 
Knyazev, P.; Ullrich, A.; Faissner, A. Receptor Protein Tyrosine Phosphatases Are 
Expressed by Cycling Retinal Progenitor Cells and Involved in Neuronal Development 
of Mouse Retina. Neuroscience 2008, 152 (3), 618–645. 
Hu, Q.-D.; Ang, B.-T.; Karsak, M.; Hu, W.-P.; Cui, X.-Y.; Duka, T.; Takeda, Y.; Chia, 
W.; Sankar, N.; Ng, Y.-K.; et al. F3/contactin Acts as a Functional Ligand for Notch 
during Oligodendrocyte Maturation. Cell 2003, 115 (2), 163–175. 
Hura, G. L.; Menon, A. L.; Hammel, M.; Rambo, R. P.; Poole, F. L.; Tsutakawa, S. E.; 
Jr, F. E. J.; Classen, S.; Frankel, K. A.; Hopkins, R. C.; et al. NIH Public Access. 2011, 
6 (8), 606–612. 
Ishikawa, M.; Sawada, Y.; Yoshitomi, T. Structure and Function of the 
Interphotoreceptor Matrix Surrounding Retinal Photoreceptor Cells. Exp. Eye Res. 2015, 
133, 3–18. 
Jiang, K.; Wright, K. L.; Zhu, P.; Szego, M. J.; Bramall, A. N.; Hauswirth, W. W.; Li, 
Q.; Egan, S. E.; McInnes, R. R. STAT3 Promotes Survival of Mutant Photoreceptors in 
Inherited Photoreceptor Degeneration Models. Proc Natl Acad Sci USA 2014, 111 (52), 
E5716–E5723. 
Johnson, K. G.; Tenney, A. P.; Ghose, A.; Duckworth, A. M.; Higashi, M. E.; Parfitt, K.; 
Marcu, O.; Heslip, T. R.; Marsh, J. L.; Schwarz, T. L.; et al. The HSPGs Syndecan and 
Dallylike Bind the Receptor Phosphatase LAR and Exert Distinct Effects on Synaptic 
Development. Neuron 2006, 49 (4), 517–531. 
Kaneko-Goto, T.; Yoshihara, S.-I.; Miyazaki, H.; Yoshihara, Y. BIG-2 Mediates 
Olfactory Axon Convergence to Target Glomeruli. Neuron 2008, 57 (6), 834–846. 
Kennedy, B.; Malicki, J. What Drives Cell Morphogenesis: A Look inside the Vertebrate 
Photoreceptor. Dev. Dyn. 2009, 238 (9), 2115–2138. 
Kramer, R. H.; Molokanova, E. Modulation of Cyclic-Nucleotide-Gated Channels and 
 115 
 
Regulation of Vertebrate Phototransduction. J. Exp. Biol. 2001, 204 (Pt 17), 2921–2931. 
Krissinel, E.; Henrick, K. Inference of Macromolecular Assemblies from Crystalline 
State. J. Mol. Biol. 2007, 372, 774–797. 
Krueger, N. X.; Saito, H. A Human Transmembrane Protein-Tyrosine-Phosphatase, PTP 
Zeta, Is Expressed in Brain and Has an N-Terminal Receptor Domain Homologous to 
Carbonic Anhydrases. Proc. Natl. Acad. Sci. U. S. A. 1992, 89 (16), 7417–7421. 
Kulahin, N.; Kristensen, O.; Rasmussen, K. K.; Olsen, L.; Rydberg, P.; Vestergaard, B.; 
Kastrup, J. S.; Berezin, V.; Bock, E.; Walmod, P. S.; et al. Structural Model and Trans-
Interaction of the Entire Ectodomain of the Olfactory Cell Adhesion Molecule. Structure 
2011, 19 (2), 203–211. 
Kumar, V.; Cheng, P.; Condamine, T.; Mony, S.; Languino, L. R.; McCaffrey, J. C.; 
Hockstein, N.; Guarino, M.; Masters, G.; Penman, E.; et al. CD45 Phosphatase Inhibits 
STAT3 Transcription Factor Activity in Myeloid Cells and Promotes Tumor-Associated 
Macrophage Differentiation. Immunity 2016, 44 (2), 303–315. 
Lamprianou, S.; Vacaresse, N.; Suzuki, Y.; Meziane, H.; Buxbaum, J. D.; Schlessinger, 
J.; Harroch, S. Receptor Protein Tyrosine Phosphatase Gamma Is a Marker for Pyramidal 
Cells and Sensory Neurons in the Nervous System and Is Not Necessary for Normal 
Development. Mol. Cell. Biol. 2006, 26 (13), 5106–5119. 
Lamprianou, S.; Chatzopoulou, E.; Thomas, J.-L.; Bouyain, S.; Harroch, S. A Complex 
between Contactin-1 and the Protein Tyrosine Phosphatase PTPRZ Controls the 
Development of Oligodendrocyte Precursor Cells. Proc. Natl. Acad. Sci. U. S. A. 2011, 
108 (42), 17498–17503. 
Laskowski, R. A.; Swindells, M. B. LigPlot + : Multiple Ligand À Protein Interaction 
Diagrams for Drug Discovery. 2011, 2778–2786. 
Lawrence, M. C.; Colman, P. M. Shape Complementarity at Protein/protein Interfaces. 
J. Mol. Biol. 1993, 234 (4), 946–950. 
Lee, S.; Takeda, Y.; Kawano, H.; Hosoya, H.; Nomoto, M.; Fujimoto, D.; Takahashi, N.; 
Watanabe, K. Expression and Regulation of a Gene Encoding Neural Recognition 
Molecule NB-3 of the contactin/F3 Subgroup in Mouse Brain. Gene 2000, 245 (2), 253–
266. 
Lein, E. S.; Hawrylycz, M. J.; Ao, N.; Ayres, M.; Bensinger, A.; Bernard, A.; Boe, A. F.; 
Boguski, M. S.; Brockway, K. S.; Byrnes, E. J.; et al. Genome-Wide Atlas of Gene 
Expression in the Adult Mouse Brain. Nature 2007, 445 (7124), 168–176. 
Leone, P.; Comoletti, D.; Ferracci, G.; Conrod, S.; Garcia, S. U.; Taylor, P.; Bourne, Y.; 
Marchot, P. Structural Insights into the Exquisite Selectivity of Neurexin/neuroligin 
Synaptic Interactions. EMBO J. 2010, 29 (14), 2461–2471. 
Levi-Montalcini, R. Effects of Mouse Tumor Transplantation on the Nervous System. 
Ann. N. Y. Acad. Sci. 1952, 55 (2), 330–344. 
Li, H.; Takeda, Y.; Niki, H.; Ogawa, J.; Kobayashi, S.; Kai, N.; Akasaka, K.; Asano, M.; 
 116 
 
Sudo, K.; Iwakura, Y.; et al. Aberrant Responses to Acoustic Stimuli in Mice Deficient 
for Neural Recognition Molecule NB-2. Eur. J. Neurosci. 2003, 17 (5), 929–936. 
London, A.; Benhar, I.; Schwartz, M. The Retina as a Window to the Brain-from Eye 
Research to CNS Disorders. Nat. Rev. Neurol. 2013, 9 (1), 44–53. 
Longo, P. A.; Kavran, J. M.; Kim, M.-S.; Leahy, D. J. Transient Mammalian Cell 
Transfection with Polyethylenimine (PEI). Methods Enzymol. 2013, 529, 227–240. 
Lorenzetto, E.; Moratti, E.; Vezzalini, M.; Harroch, S.; Sorio, C.; Buffelli, M. 
Distribution of Different Isoforms of Receptor Protein Tyrosine Phosphatase γ (Ptprg-
RPTP γ) in Adult Mouse Brain: Upregulation during Neuroinflammation. Brain Struct. 
Funct. 2013. 
Mackerell,  a D.; Jr; Bashford, D.; Bellott, M.; Dunbrack, R. L.; Evanseck, J. D.; Field, 
M. J.; Fischer, S.; Gao, J.; Guo, H.; et al. All-Atom Empirical Potential for Molecular 
Modeling and Dynamics Studies of Proteins. J Phys Chem B 1998, 102 (97), 3586–3616. 
Matsugo, S.; Matsuura, T.; Sarna, T.; Vargas, F.; Epe, B.; Schiffmann, D.; Wild, D.; 
Bommakanti, A.; Mitchell, D. Structural Basis for Notch1 Engagement of Delta-like 4. 
2015, 347 (6224), 847–854. 
McCoy, A. J.; Grosse-Kunstleve, R. W.; Adams, P. D.; Winn, M. D.; Storoni, L. C.; 
Read, R. J. Phaser Crystallographic Software. J. Appl. Crystallogr. 2007, 40 (4), 658–
674. 
Mirenda, M.; Toffali, L.; Montresor, A.; Scardoni, G.; Sorio, C.; Laudanna, C. Protein 
Tyrosine Phosphatase Receptor Type γ Is a JAK Phosphatase and Negatively Regulates 
Leukocyte Integrin Activation. J. Immunol. 2015, 194 (5), 2168–2179. 
Mohebiany, A. N.; Nikolaienko, R. M.; Bouyain, S.; Harroch, S. Receptor-Type Tyrosine 
Phosphatase Ligands: Looking for the Needle in the Haystack. FEBS J. 2013, 280 (2), 
388–400. 
Molokanova, E.; Trivedi, B.; Savchenko, A.; Kramer, R. H. Modulation of Rod 
Photoreceptor Cyclic Nucleotide-Gated Channels by Tyrosine Phosphorylation. J. 
Neurosci. 1997, 17 (23), 9068–9076. 
Molokanova, E.; Maddox, F.; Luetje, C. W.; Kramer, R. H. Activity-Dependent 
Modulation of Rod Photoreceptor Cyclic Nucleotide- Gated Channels Mediated by 
Phosphorylation of a Specific Tyrosine Residue. J Neurosci 1999, 19 (12), 4786–4795. 
Nam, H. J.; Poy, F.; Krueger, N. X.; Saito, H.; Frederick, C. a. Crystal Structure of the 
Tandem Phosphatase Domains of RPTP LAR. Cell 1999, 97 (4), 449–457. 
Nam, H.-J. Structural Basis for the Function and Regulation of the Receptor Protein 
Tyrosine Phosphatase CD45. J. Exp. Med. 2005, 201 (3), 441–452. 
Nans, A.; Einheber, S.; Salzer, J. L.; Stokes, D. L. Electron Tomography of Paranodal 
Septate-like Junctions and the Associated Axonal and Glial Cytoskeletons in the Central 
Nervous System. J. Neurosci. Res. 2011, 89 (3), 310–319. 
 117 
 
Ortiz, B.; Fabius, A. W. M.; Wu, W. H.; Pedraza, A.; Brennan, C. W.; Schultz, N.; Pitter, 
K. L.; Bromberg, J. F.; Huse, J. T.; Holland, E. C.; et al. Loss of the Tyrosine Phosphatase 
PTPRD Leads to Aberrant STAT3 Activation and Promotes Gliomagenesis. Proc. Natl. 
Acad. Sci. U. S. A. 2014, 111 (22), 8149–8154. 
Osterfield, M.; Egelund, R.; Young, L. M.; Flanagan, J. G. Interaction of Amyloid 
Precursor Protein with Contactins and NgCAM in the Retinotectal System. Development 
2008, 135 (6), 1189–1199. 
Osterhout, J. A.; Stafford, B. K.; Nguyen, P. L.; Yoshihara, Y.; Huberman, A. D. 
Contactin-4 Mediates Axon-Target Specificity and Functional Development of the 
Accessory Optic System. Neuron 2015, 86 (4), 985–999. 
Otwinowski, Z.; Minor, W. Macromolecular Crystallography Part A; Methods in 
Enzymology; Elsevier, 1997; Vol. 276. 
Özkan, E.; Chia, P. H.; Wang, R. R.; Goriatcheva, N.; Borek, D.; Otwinowski, Z.; Walz, 
T.; Shen, K.; Garcia, K. C. Extracellular Architecture of the SYG-1/SYG-2 Adhesion 
Complex Instructs Synaptogenesis. Cell 2014, 156 (3), 482–494. 
Peles, E.; Nativ, M.; Campbell, P. L.; Sakurai, T.; Martinez, R.; Lev, S.; Clary, D. O.; 
Schilling, J.; Barnea, G.; Plowman, G. D.; et al. The Carbonic Anhydrase Domain of 
Receptor Tyrosine Phosphatase Beta Is a Functional Ligand for the Axonal Cell 
Recognition Molecule Contactin. Cell 1995, 82 (2), 251–260. 
Pettersen, E. F.; Goddard, T. D.; Huang, C. C.; Couch, G. S.; Greenblatt, D. M.; Meng, 
E. C.; Ferrin, T. E. UCSF Chimera - A Visualization System for Exploratory Research 
and Analysis. J. Comput. Chem. 2004, 25 (13), 1605–1612. 
Pinzon-Guzman C, Xing T, Zhang SS, B. C. Regulation Of Rod Photoreceptor 
Differentiation By STAT3 Is Controlled By A Tyrosine Phosphatase. 2011, 18 (11), 
1492–1501. 
Sakurai, K.; Toyoshima, M.; Ueda, H.; Matsubara, K.; Takeda, Y.; Karagogeos, D.; 
Shimoda, Y.; Watanabe, K. Contribution of the Neural Cell Recognition Molecule NB-
3 to Synapse Formation between Parallel Fibers and Purkinje Cells in Mouse. Dev. 
Neurobiol. 2009, 69 (12), 811–824. 
Sakurai, K.; Toyoshima, M.; Takeda, Y.; Shimoda, Y.; Watanabe, K. Synaptic Formation 
in Subsets of Glutamatergic Terminals in the Mouse Hippocampal Formation Is Affected 
by a Deficiency in the Neural Cell Recognition Molecule NB-3. Neurosci. Lett. 2010, 
473 (2), 102–106. 
Sakurai, T.; Lustig, M.; Nativ, M.; Hemperly, J. J.; Schlessinger, J.; Peles, E.; Grumet, 
M. Induction of Neurite Outgrowth through Contactin and Nr-CAM by Extracellular 
Regions of Glial Receptor Tyrosine Phosphatase β. J. Cell Biol. 1997, 136 (4), 907–918. 
Sali, A.; Blundell, T. L. Comparative Protein Modelling by Satisfaction of Spatial 
Restraints. J. Mol. Biol. 1993, 234 (3), 779–815. 
Sallee, J. L.; Wittchen, E. S.; Burridge, K. Regulation of Cell Adhesion by Protein-
 118 
 
Tyrosine Phosphatases II. Cell-Cell Adhesion. J. Biol. Chem. 2006, 281 (24), 16189–
16192. 
Sarkar, G.; Sommer, S. S. The “Megaprimer” Method of Site-Directed Mutagenesis. 
Biotechniques 1990, 8 (4), 404–407. 
Savchenko,  a; Kraft, T. W.; Molokanova, E.; Kramer, R. H. Growth Factors Regulate 
Phototransduction in Retinal Rods by Modulating Cyclic Nucleotide-Gated Channels 
through Dephosphorylation of a Specific Tyrosine Residue. Proc. Natl. Acad. Sci. U. S. 
A. 2001, 98, 5880–5885. 
Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T,  et al. Fiji: 
An Open-Source Platform for Biological-Image Analysis. Nat. Publ. Group. 2003, 9 (7), 
187. 
Schindelin, J.; Arganda-Carreras, I.; Frise, E.; Kaynig, V.; Longair, M.; Pietzsch, T.; 
Preibisch, S.; Rueden, C.; Saalfeld, S.; Schmid, B.; et al. Fiji: An Open Source Platform 
for Biological Image Analysis. Nat. Methods 2012, 9 (7), 676–682. 
Schlessinger, J. Receptor Tyrosine Kinases: Legacy of the First Two Decades. Cold 
Spring Harb. Perspect. Biol. 2014, 6 (3), a008912–a008912. 
Schneidman-Duhovny, D.; Hammel, M.; Tainer, J. A.; Sali, A. Accurate SAXS Profile 
Computation and Its Assessment by Contrast Variation Experiments. Biophys. J. 2013, 
105 (4), 962–974. 
Shimoda, Y.; Watanabe, K. Contactins: Emerging Key Roles in the Development and 
Funciton of the Nervous System. Cell Adh. Migr. 2009, 3 (1), 64–70. 
Shimoda, Y.; Koseki, F.; Itoh, M.; Toyoshima, M.; Watanabe, K. A Cis-Complex of NB-
2/contactin-5 with Amyloid Precursor-like Protein 1 Is Localized on the Presynaptic 
Membrane. Neurosci. Lett. 2012, 510 (2), 148–153. 
Söderberg, O.; Leuchowius, K. J.; Gullberg, M.; Jarvius, M.; Weibrecht, I.; Larsson, L. 
G.; Landegren, U. Characterizing Proteins and Their Interactions in Cells and Tissues 
Using the in Situ Proximity Ligation Assay. Methods 2008, 45 (3), 227–232. 
Sonnenburg, E. D.; Bilwes, A.; Hunter, T.; Noel, J. P. The Structure of the Membrane 
Distal Phosphatase Domain of RPTPalpha Reveals Interdomain Flexibility and an SH2 
Domain Interaction Region. Biochemistry 2003, 42 (26), 7904–7914. 
Stella, S. L.; Vila, A.; Hung, A. Y.; Rome, M. E.; Huynh, U.; Sheng, M.; Kreienkamp, 
H.-J.; Brecha, N. C. Association of Shank 1A Scaffolding Protein with Cone 
Photoreceptor Terminals in the Mammalian Retina. PLoS One 2012, 7 (9), e43463. 
Takeda, Y.; Akasaka, K.; Lee, S.; Kobayashi, S.; Kawano, H.; Murayama, S.; Takahashi, 
N.; Hashimoto, K.; Kano, M.; Asano, M.; et al. Impaired Motor Coordination in Mice 
Lacking Neural Recognition Molecule NB-3 of the contactin/F3 Subgroup. J. Neurobiol. 
2003, 56 (3), 252–265. 
Tonks, N. K. Protein Tyrosine Phosphatases: From Genes, to Function, to Disease. Nat. 
Rev. Mol. Cell Biol. 2006, 7 (11), 833–846. 
 119 
 
Toyoshima, M.; Sakurai, K.; Shimazaki, K.; Takeda, Y.; Nakamoto, M.; Serizawa, S.; 
Shimoda, Y.; Watanabe, K. Preferential Localization of Neural Cell Recognition 
Molecule NB-2 in Developing Glutamatergic Neurons in the Rat Auditory Brainstem. J. 
Comp. Neurol. 2009, 513 (4), 349–362. 
Traka, M.; Goutebroze, L.; Denisenko, N.; Bessa, M.; Nifli, A.; Havaki, S.; Iwakura, Y.; 
Fukamauchi, F.; Watanabe, K.; Soliven, B.; et al. Association of TAG-1 with Caspr2 Is 
Essential for the Molecular Organization of Juxtaparanodal Regions of Myelinated 
Fibers. J. Cell Biol. 2003, 162 (6), 1161–1172. 
Volkov, V. V.; Svergun, D. I. Uniqueness of Ab Initio Shape Determination in Small-
Angle Scattering. J. Appl. Crystallogr. 2003, 36 (3), 860–864. 
Winn, M. D.; Ballard, C. C.; Cowtan, K. D.; Dodson, E. J.; Emsley, P.; Evans, P. R.; 
Keegan, R. M.; Krissinel, E. B.; Leslie, A. G. W.; McCoy, A.; et al. Overview of the 
CCP 4 Suite and Current Developments. Acta Crystallogr. Sect. D Biol. Crystallogr. 
2011, 67 (4), 235–242. 
Yamagata, M.; Sanes, J. R. Expanding the Ig Superfamily Code for Laminar Specificity 
in Retina: Expression and Role of Contactins. J. Neurosci. 2012, 32 (41), 14402–14414. 
Yan, C.-M.; Zhao, Y.-L.; Cai, H.-Y.; Miao, G.-Y.; Ma, W. Blockage of PTPRJ Promotes 
Cell Growth and Resistance to 5-FU through Activation of JAK1/STAT3 in the Cervical 
Carcinoma Cell Line C33A. Oncol. Rep. 2015, 1737–1744. 
Ye, H.; Tan, Y. L. J.; Ponniah, S.; Takeda, Y.; Wang, S.-Q.; Schachner, M.; Watanabe, 
K.; Pallen, C. J.; Xiao, Z.-C. Neural Recognition Molecules CHL1 and NB-3 Regulate 
Apical Dendrite Orientation in the Neocortex via PTP Alpha. EMBO J. 2008, 27 (1), 
188–200. 
Yoshihara, Y.; Kawasaki, M.; Tani, A.; Tamada, A.; Nagata, S.; Kagamiyama, H.; Mori, 
K. BIG-1: A New TAG-1/F3-Related Member of the Immunoglobulin Superfamily with 
Neurite Outgrowth-Promoting Activity. Neuron 1994, 13 (2), 415–426. 
Zayas-Santiago, A.; Kang Derwent, J. J. Preservation of Intact Adult Rat Photoreceptors 
in Vitro: Study of Dissociation Techniques and the Effect of Light. Mol. Vis. 2009, 15 
(December 2008), 1–9. 
Zhang, W.; Savelieva, K. V; Tran, D. T.; Pogorelov, V. M.; Cullinan, E. B.; Baker, K. 
B.; Platt, K. a; Hu, S.; Rajan, I.; Xu, N.; et al. Characterization of PTPRG in Knockdown 
and Phosphatase-Inactive Mutant Mice and Substrate Trapping Analysis of PTPRG in 
Mammalian Cells. PLoS One 2012, 7 (9), e45500. 
Zhang, X.; Guo, A.; Yu, J.; Possemato, A.; Chen, Y.; Zheng, W.; Polakiewicz, R. D.; 
Kinzler, K. W.; Vogelstein, B.; Velculescu, V. E.; et al. Identification of STAT3 as a 
Substrate of Receptor Protein Tyrosine Phosphatase T. Proc. Natl. Acad. Sci. U. S. A. 
2007, 104 (10), 4060–4064. 
Zuko, A.; Bouyain, S.; van der Zwaag, B.; Burbach, J. P. H. Contactins: Structural 
Aspects in Relation to Developmental Functions in Brain Disease.; 2011; Vol. 84. 
 120 
 
VITA 
 
Roman M. Nikolaienko was born on July 16, 1986, in Kyiv, Ukraine. In 2007, he 
obtained his Bachelor of Arts degree in Industrial Biotechnology from National 
Technical University of Ukraine “Kyiv Polytechnic Institute” and graduated from 
National Technical University of Ukraine “Kyiv Polytechnic Institute” with a Master of 
Science in Biotechnology in 2009. He worked as a research assistant at Bioinformatics 
division of Biotechnology Department in National Technical University of Ukraine 
“Kyiv Polytechnic Institute” from 2009 to 2010. 
He began graduate school in 2010 at the School of Biological Sciences of the 
University of Missouri Kansas City and joined the laboratory of Dr. Samuel Bouyain in 
2010. During his PhD program, he worked on the structural and functional investigation 
of Receptor Protein Tyrosine Phosphatase Gamma and its ligands Contactins.   
 
 
 
 
 
 
 
 
  
 
